{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.15125"}, {"@name": "filename", "#text": "21513_350209.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DE SANTA CATARINA \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM ODONTOLOGIA \n\nMESTRADO EM IMPLANTODONTIA \n\n \n\n \n\n \n\n \n\nMAR\u00cdA ELISA GAL\u00c1RRAGA VINUEZA \n\n \n\n \n\n \n\n \n\nS\u00cdNTESE, CARACTERIZA\u00c7\u00c3O E CAPACIDADE DE INIBI\u00c7\u00c3O \n\nDE BIOFILME POR BIOVIDRO ATIVO 58S ATRAV\u00c9S DA \n\nINCORPORA\u00c7\u00c3O DE COMPOSTOS ORG\u00c2NICOS E \n\nINORG\u00c2NICOS  \n\n \n\n \n\n \n\nDisserta\u00e7\u00e3o de Mestrado \n\n \n\n \n\n \n\n \n\nOrientador: Prof. Dr. Ricardo de Souza Magini \n\nCo-orientador: Prof. Dr. J\u00falio C\u00e9sar Matias de Souza  \n\n \n\n \n\n \n\n \n \n\n \n\nFlorian\u00f3polis \n\n2017 \n\n  \n\n\n\n  \n\n\n\nMar\u00eda Elisa Gal\u00e1rraga Vinueza  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nS\u00cdNTESE, CARACTERIZA\u00c7\u00c3O E CAPACIDADE DE INIBI\u00c7\u00c3O \n\nDE BIOFILME POR BIOVIDRO ATIVO 58S ATRAV\u00c9S DA \n\nINCORPORA\u00c7\u00c3O DE COMPOSTOS ORG\u00c2NICOS E \n\nINORG\u00c2NICOS  \n \n\n \n\n \nDisserta\u00e7\u00e3o submetida ao Programa de \n\nP\u00f3s-Gradua\u00e7\u00e3o da Universidade \n\nFederal de Santa Catarina para a \n\nobten\u00e7\u00e3o do Grau de Mestre em \n\nOdontologia na \u00e1rea de concentra\u00e7\u00e3o \n\nde Implantodontia. \n\nOrientador: Prof. Dr. Ricardo de Souza \n\nMagini \n\nCoorientador: Prof\u00aa. Dr. J\u00falio C\u00e9sar \n\nMatias de Souza  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\nFlorian\u00f3polis \n\n2017  \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFicha de identifica\u00e7\u00e3o da obra elaborada pelo autor \n\natrav\u00e9s do Programa de Gera\u00e7\u00e3o Autom\u00e1tica da Biblioteca Universit\u00e1ria \n\nda UFSC. \n\n \n\n \n\nGal\u00e1rraga Vinueza, Mar\u00eda Elisa  \n\nS\u00edntese, caracteriza\u00e7\u00e3o e capacidade de inibi\u00e7\u00e3o de biofilme \n\npor biovidro ativo 58S atrav\u00e9s da incorpora\u00e7\u00e3o de compostos \n\norg\u00e2nicos e inorg\u00e2nicos  \n\n/ Mar\u00eda Elisa Gal\u00e1rraga Vinueza; orientador, Ricardo de \n\nSouza Magini; coorientador, J\u00falio C\u00e9sar Matias de Souza. \n\n- Florian\u00f3polis, SC, 2017. \n\n112 p. \n\n \n\nDisserta\u00e7\u00e3o (mestrado acad\u00eamico) - Universidade Federal \n\nde Santa Catarina, Centro de Ci\u00eancias da Sa\u00fade. Programa de \n\nP\u00f3s Gradua\u00e7\u00e3o em Odontologia. \n\n \n\nInclui refer\u00eancias \n\n1. Odontologia. 2. Biomaterial. 3. Biovidro. 4. Osso. 5. \n\nBiofilme oral. I. Magini, Ricardo de Souza. II. Souza, J\u00falio C\u00e9sar \n\nMatias. III. Universidade Federal de Santa Catarina. Programa de \n\nP\u00f3s-Gradua\u00e7\u00e3o em Odontologia. IV. T\u00edtulo. \n\n \n\n  \n\n\n\n  \n\n\n\n \n\n  \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nEste trabajo est\u00e1 dedicado al infinito amor \n\ny fe que tengo por Dios, con \u00c9l y en \u00c9l \n\nsomos la herramienta para mejorar este \n\nmundo.  \n\n  \n\n\n\n\n\nAGRADECIMENTOS \n\nRealmente \u00e9 imposs\u00edvel descrever todo meu agradecimento com \n\npalavras. O sentimento com certeza \u00e9 muito mais forte do que esta \n\np\u00e1gina pode transmitir... \n\nEn primer lugar quiero agradecer a DIOS por iluminar cada d\u00eda \n\nde mis 26 a\u00f1os de vida. Gracias SE\u00d1OR por darme tanto, por amarme, \n\npor hacerme sentir enamorada de esta vida, gracias por bendecirme con \n\nuna familia tan maravillosa, gracias por darme amigos que son tesoros \n\ninigualables, gracias por darme acceso al conocimiento y a la ciencia, \n\ngracias por colocar en mi vida a mis profesores que me han hecho \n\ndescubrir tu infinito mundo y querer ser mejor cada d\u00eda. GRACIAS por \n\nser mi raz\u00f3n de vivir. Esta vida no podr\u00eda ser mejor.  \n\nA mis pap\u00e1s, no puedo ni explicar el amor y agradecimiento que \n\nsiento por ustedes. Me han hecho sentir amada desde que fui una \n\npeque\u00f1a c\u00e9lula. Ustedes me esperaron con tanta esperanza llenando mi \n\nesp\u00edritu con esa ilusi\u00f3n, lo cual hasta el d\u00eda de hoy me hace saber que en \n\nesta vida tengo un prop\u00f3sito, una raz\u00f3n de ser. Mam\u00e1, eres todo lo que \n\nquiero llegar a ser. Gracias por ense\u00f1arme desde la primera vez que me \n\ntuviste en tus brazos que deb\u00eda amar, cuidar y cultivar mi cuerpo porque \n\nes el templo de DIOS. Gracias por tu mirada llena de fuerza y energ\u00eda \n\nque me ense\u00f1a d\u00eda a d\u00eda a amar incondicionalmente, a ser perseverante, \n\na luchar por mis ideales, a creer en m\u00ed. Pap\u00e1, mi ejemplo a seguir. \n\nGracias por tu infinito amor, tu hermosa sonrisa que alegra mis d\u00edas. Tu \n\nenerg\u00eda puede atravesar cualquier barrera, desde el coraz\u00f3n m\u00e1s duro \n\nhasta el m\u00e1s blando. T\u00fa me ense\u00f1aste a llegar al coraz\u00f3n de las personas \n\ncon un saludo, un abrazo, una sonrisa. T\u00fa me ense\u00f1aste a esperar lo \n\nmejor de todas las personas y a intentar ser la mejor versi\u00f3n de m\u00ed \n\nmisma para ser un excelente ser humano antes que cualquier logro \n\nacad\u00e9mico o profesional. Gracias por iluminar ni coraz\u00f3n con tu amor y \n\nalegr\u00eda, pienso en ti y sonri\u00f3 todos los d\u00edas. Hermana, quien tiene la \n\notra parte de mi coraz\u00f3n. T\u00fa le pediste a Dios que llegue a este mundo. \n\nLlegu\u00e9 para ser tu compa\u00f1era, tu hombro, tu mano derecha, tu respaldo. \n\nTienes el coraz\u00f3n m\u00e1s puro que he conocido, del cual intento aprender \n\ncada d\u00eda para ser m\u00e1s bondadosa y generosa. Nuestros corazones est\u00e1n \n\nunidos, siempre juntas para enfrentar cualquier adversidad. Gracias por \n\nser la mejor hermana del mundo y protegerme.  \n\nPrezados professores, obrigada por todo seu exemplo e ensino. \u00c9 \n\num orgulho para mi ser sua aluna. Professor Magini obrigada por ser \n\nmeu orientador, por ser a pessoa que sempre sabe como motivar-me no \n\nmomento exato. Tanto eu como meu pai sentimos seu carinho a primeira \n\n\n\nvez que entramos no CEPID. O professor me deu a benvinda no Brasil, \n\ndesde o come\u00e7o eu soube que um largo caminho de aprendizagem me \n\nesperava do seu lado. Professor C\u00e9sar, obrigada por ser um exemplo de \n\npaix\u00e3o pelo ensino, \u00e9 um professor que me inspira e motiva para querer \n\nser professora num futuro. Obrigada por sempre cuidar de todos seus \n\nalunos no CEPID. Voc\u00ea faz que todos nos sintamos numa fam\u00edlia. \n\nProfessor Bianchini, obrigada por seu constante ensino dia a dia na \n\ncl\u00ednica, na pesquisa e na vida. Obrigada pela sinceridade, o professor me \n\nensinou a procurar o caminho da excel\u00eancia, a tentar dar o melhor de \n\nmim e tomar uma postura mais forte na vida. Cada dia eu fico mais \n\ninspirada para continuar pesquisando com o professor. Professor \n\nCardoso, obrigada por ser meu orientador espiritual. Por ensinar para \n\nmim semana traz semana a palavra do nosso CRIADOR. Obrigada, por \n\nser meu exemplo de humildade, sabedoria e equil\u00edbrio. O professor foi \n\num apoio inigual\u00e1vel no Brasil, obrigada por todo seu carinho. \n\nProfessor Fredel, obrigada por seu apoio e carinho na minha pesquisa, \n\no professor foi um pilar fundamental para mim. Professor J\u00falio, \n\nobrigada por sua co-orienta\u00e7\u00e3o e apoio, sempre esteve do meu lado no \n\nmeu mestrado.   \n\nObrigada a meus colegas, Adri por ser mi hermana en Brasil y \n\ntener un coraz\u00f3n tan grande y transparente que nunca se cansa de hacer \n\nfeliz a los dem\u00e1s. Karin, gracias por tu apoyo, bondad, eres una amiga \n\nincre\u00edble que me ense\u00f1a cada d\u00eda. Edwin, gracias por siempre estar a mi \n\nlado, apoy\u00e1ndome con tu radiante energ\u00eda que siempre me da fuerza. \n\nNicol\u00e1s, gracias por tu nobleza, tu coraz\u00f3n gigante y por siempre estar \n\ndispuesto a ayudarme y cuidarme.  \n\nCarol Morsch, obrigada por entrar na minha vida, voc\u00ea \u00e9 um \n\nexemplo de integridade para todos, sempre quero seguir teu exemplo. \n\nSua amizade \u00e9 um presente de Deus. Mari, obrigada por tua pureza, \n\nsinceridade, por teu olhar cheio de amor que sempre me d\u00e1 alegria e me \n\nlembra que neste mundo existem pessoas inigual\u00e1veis como voc\u00ea. \n\nRenata, minha dupla, n\u00f3s aprendemos tanto juntas. Espero continuar \n\naprendendo a vida inteira com voc\u00ea. Obrigada por sua amizade, voc\u00ea \u00e9 \n\numa amiga incondicional que me ensina que devemos lutar por nossos \n\ndesejos. A todos os colegas do CEPID, Nathi, Paty, Miguel, Artur, \n\nGaby, Bruna, Gabriel, Juan, Suzeli, Rafa, e Sil, obrigada por sua \n\namizade e por sua generosidade de tempo, conhecimento e carinho. \n\nVoc\u00eas s\u00e3o um presente de Deus na minha vida.  \n\n  \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\"E n\u00e3o vos conformeis com este \n\nmundo, mas transformai-vos pela \n\nrenova\u00e7\u00e3o do vosso entendimento, para \n\nque experimenteis qual seja a boa, \n\nagrad\u00e1vel e perfeita vontade de Deus.\"  \n\nRomanos 12:2 \n\n\n\n  \n\n\n\nRESUMO \n\nO biovidro ativo \u00e9 um biomaterial promissor que tem mostrado \n\nexcelentes efeitos osteog\u00eanicos, angiog\u00eanicos e antibacterianos para ser \n\naplicado em procedimentos de repara\u00e7\u00e3o \u00f3ssea em diversas \u00e1reas. Em \n\nimplantologia oral, infec\u00e7\u00f5es podem ocorrer ap\u00f3s procedimentos \n\ncir\u00fargicos em decorr\u00eancia da presen\u00e7a de biofilmes orais incluindo \n\nesp\u00e9cies patog\u00eanicas. Sendo assim, este trabalho teve como principal \n\nobjetivo desenvolver biomateriais \u00e0 base de um biovidro nano-\n\nestruturado para incorpora\u00e7\u00e3o de compostos com potencial anti-\n\nbiofilme. O biovidro ativo 58S foi modificado incorporando brometo, \n\ncompostos derivados do cranberry e da pr\u00f3polis na sua estrutura. As \n\namostras foram caracterizadas por meio de an\u00e1lise qu\u00edmica, textural e \n\nf\u00edsica. O potencial anti-biofime do biovidro ativo foi determinado \n\natrav\u00e9s de q-PCR e an\u00e1lise microsc\u00f3pico. A reatividade qu\u00edmica foi \n\navaliada por meio de an\u00e1lise qu\u00edmica, microsc\u00f3pica e da propor\u00e7\u00e3o \n\nCa/P. As amostras do biovidro ativo incorporando brometo, cranberry \n\nPACS e pr\u00f3polis mostraram uma distribui\u00e7\u00e3o de tamanho de part\u00edculas, \n\nestrutura f\u00edsica e composi\u00e7\u00e3o qu\u00edmica apropriadas. O biovidro ativo \n\nmodificado com 5wt% CaBr2 inibiu a prolifera\u00e7\u00e3o de S. mitis, V. \n\nparvula, P. gingivais, S.gordoni, A. viscosus, e F. Nucleatum. Uma \n\nsignificativa forma\u00e7\u00e3o de hidroxiapatita carbonatada foi revelada nas \n\namotras do biovidro ativo mesoporoso incorporando cranberry PACS e \n\npr\u00f3polis ap\u00f3s 72 h de imers\u00e3o na solu\u00e7\u00e3o corporal simulada. Por \n\nconseguinte, a incorpora\u00e7\u00e3o de compostos inorg\u00e2nicos e org\u00e2nicos no \n\nbiovidro ativo 58S pode ser uma estrat\u00e9gia para potencializar seu efeito \n\nanti-biofilme e ser aplicado em tratamentos de reparo e infec\u00e7\u00e3o \u00f3ssea.  \n\nPalavras-chave: 1. Biovidro ativo 2. Antibiofilmes 3. Enxerto \u00f3sseo 4. \n\nS\u00ednteses sol-gel 5. Infe\u00e7\u00e3o \u00f3ssea 6. Reparo \u00f3sseo \n\n\n\n  \n\n\n\nABSTRACT \n\nBioactive glass is an attractive biomaterial that has shown excellent \n\nosteogenic, angiogenic and antibacterial effects for bone healing. One of \n\nthe main issues regarding oral surgery and bone grafting procedures are \n\nthe recurrent infections caused by oral biofilm involving pathogenic \n\nspecies. Thus, the main aim of the present study was to produce porous \n\nbioactive glasses incorporating inorganic and organic compounds in \n\ntheir chemical and physical structure to enhance anti-biofilm potential \n\nduring bone repairing procedures. The modified 58S bioactive glasses \n\nembedded bromide, cranberry PACS and propolis compounds and were \n\ncharacterized through physical, chemical and textural analysis. \n\nBioactive glass multispecies antibiofilm potential was evaluated by q-\n\nPCR analysis and microscopic observation. Chemical reactivity of the \n\nsamples was examined through chemical, microscopic and Ca/P ratio \n\nanalysis. Bioactive glasses embedding bromide, cranberry PACS and \n\npropolis showed an appropriate particle size distribution, chemical and \n\nphysical properties. Bioactive glass embedding 5wt% CaBr2 inhibited S. \n\nmitis, V. parvula, P. gingivais, S.gordoni, A. viscosus, and F. nucleatum \n\nproliferation. A significant hydroxyl-carbonate apatite layer was \n\nrevealed by mesoporous BG samples incorporating cranberry PACS and \n\npropolis compounds after immersion in simulated body fuid for 72 h. \n\nThe incorporation of inorganic and organic compounds into bioactive \n\nglass structure can be a strategy to enhance its antibiofilm potential for \n\nbone healing and infection treatment procedures.  \n\nKeywords: 1.Bioactive glass 2. Anti-biofilm agents 3. Bone graft, 4. \n\nSol-gel synthesis, 5. Bone infection, 6. Bone repair \n\n\n\n\n\nLISTA DE FIGURAS \n\nFiguras Artigo 1   \n\nFigure 1. Schematic diagram showing mesoporous BG loaded with \n\nantibacterial agents applied and delivered at infected implanted receptor \n\nsites with an acid medium to inhibit biofilm proliferation and repair \n\nbone defects. .......................................................................................... 44 \n\nFiguras Artigo 2 \n\nFigure 1. Schematic diagram showing the followed methodology to \n\nassess biofilm inhibition ........................................................................ 59 \n\nFigura 2. 58S BG Bimodal particle size distribution ........................... 62 \n\nFigura 3. EDX spectra recorded for 58S bioactive glass free of CaBr2 \n\nand including 5 or 10% CaBr2 ............................................................... 63 \n\nFigure 4. XRD spectra recorded for 58S bioactive glass samples free of \n\nCaBr2 processed at 600 or 1150 \no\nC. ...................................................... 64 \n\nFigure 5. XRD spectra recorded for 58S bioactive glass samples \n\nembedding 5% CaBr2 processed at 600 or 1150 \no\nC .............................. 64 \n\nFigure 6. XRD spectra recorded for 58S bioactive glass samples \n\nembedding 10% CaBr2 processed at 600 or 1150 \no\nC ............................ 65 \n\nFigure 7. SEM images of BG 58S 5wt % CaBr2 powder (A and B), 58S \n\nBG discs before (C, E and G) and after (D, F and H) thermal treatment \n\nincorporating 0, 5, and 10 wt % CaBr2 correspondingly ....................... 66 \n\nFigure 8. Ra, Rt roughness values, color map and 3D representation of \n\nsurface roughness for 0, 5, and 10wt% CaBr2 doped 58S BG discs after \n\nthermal treatment up to 1150\no\nC ............................................................ 67 \n\nFigure 9. Relative densities of green and sintered discs of BG 58S \n\ncontaining or not 5wt% or 10wt% CaBr2 .............................................. 68 \n\nFigure 10. . Inhibition of early and beneficial oral biofilm species on \n\n0wt% CaBr2 58S BG discs with chlorhexidine (CHX) (positive control \n\ngroup), 0wt% CaBr2 BG58S discs (negative control group), 5 or 10 wt% \n\nCaBr2 BG58S discs ............................................................................... 69 \n\nFigure 11. Inhibition of pathogen oral biofilm species on 0wt% CaBr2 \n\nBG58S discs with chlorhexidine (CHX) (positive control group), 0wt% \n\nCaBr2 BG58S discs (negative control group), and 5, 10 wt% CaBr2 \n\nBG58S discs .......................................................................................... 69 \n\n\n\nFigure 12. SEM images of multi-species biofilm adherence on BG58S \n\ndiscs with 0wt%CaBr2 (A,B), 5wt% CaBr2(C,D) and 10 wt% \n\nCaBr2(E,F) ............................................................................................. 70 \n\nFiguras Artigo 3  \n\nFigure 1. Schematic diagram showing the methodology applied in this \n\nstudy to prepare MBG incorporating propolis and cranberry PACS. .... 83 \n\nFigure 2. (A) MBG 58S particle size distribution and (B) EDX results \n\nfor 58S MBG.......................................................................................... 86 \n\nFigure 3. FTIR spectrum obtained for 58S mesoporous bioactive glasses \n\n(relevant peaks are indicated). ............................................................... 87 \n\nFigure 4. (A) N2 adsorption (red)-desorption (blue) isotherms and (B) \n\nBJH pore radius distribution curves for 58S mesoporous bioactive glass \n\nparticles. ................................................................................................. 87 \n\nFigure 5. (A-C) FESEM images of 58S MBG 58S particles at different \n\nmagnifications. In (C) nano-pores (white squares) are revealed at \n\n80,000X magnification. ......................................................................... 88 \n\nFigure 6.FESEM micrographs at 10,000X recorded on 58S MBG \n\nparticles after immersion in SBF for 8, 24 and 72 h. MBG (A) Pure and \n\ncontaining (B) 5 \u00b5g/ml cranberry PACS, (C) 10 \u00b5g/ml cranberry PACs, \n\n(D) 5\u00b5g/ml propolis and (E) 10 \u00b5g/ml propolis. Red squares exhibit \n\ncorresponding micrographs at 50,000X. ................................................ 90 \n\nFigure 7. SEM images (1,000X) and EDX analysis recorded on MBG \n\ncontaining 5 \u00b5g/ml propolis particles immersed in SBF solution for (A) \n\n8 h, (B) 24 h and (C) 72 h. ..................................................................... 91 \n\nFigure 8.  FTIR spectra obtained for 58S mesoporous bioactive glass \n\nsamples (free MBG, MBG-5 \u00b5g/ml propolis and MBG-5 \u00b5g/ml \n\ncranberry PACS) before and after 72 h of SBF immersion. (Red circle \n\nidentifies the double peak characteristic of HCAp formation)............... 92 \n\n  \n\n\n\nLISTA DE TABELAS \n\nArtigo 1  \n\nTable I. Summary of Relevant Studies on Antibiotic-Loaded Bioactive \n\nGlasses to Prevent Infection .................................................................. 40 \n\nArtigo 3   \n\nTable 1.  Chemical composition of the SBF stock solution [40] .......... 85 \n\nTable 2. Ca/P elemental concentration ratio of samples before and after \n\nSBF immersion for 0, 8, 24 and 72 h .................................................... 91 \n\n\n\n\n\nLISTA DE ABREVIATURAS E SIGLAS \n\nBET M\u00e9todo Brunaeur-Emmet-Teller  \n\nBJH M\u00e9todo Barrett-Joyner-Halenda \n\nBG Biovidro ativo  \n\nEDX Espectroscopia de Energia Dispersiva \n\nEPS Sust\u00e2ncias polim\u00e9ricas extracelulares \n\nFTIR Espectroscopia no infravermelho por transforma\u00e7\u00e3o de \n\nFourier \n\nCHA Hidroxiapatita carbonatada \n\nCaBr2 Brometo de C\u00e1lcio \n\nMBG Biovidro Mesoporoso  \n\nMEC Matriz extracelular \n\nMEV Microscopia eletr\u00f4nica de varredura \n\nMin Minutos \n\nMTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-\n\n2-(4-sulfophenyl)-2H-tetrazolium \n\nNPs Nano part\u00edculas \n\nPBS Solu\u00e7\u00e3o tamp\u00e3o de fosfato \n\npH Potencial hidrogeni\u00f4nico \n\nOS Solu\u00e7\u00e3o de penicilina/estreptomicina \n\nq-PCR Rea\u00e7\u00e3o em cadeia da polimerase quantitativa \n\nRa Rugosidade m\u00e9dia \n\nRt Rugosidade total \n\nROG Regenera\u00e7\u00e3o \u00f3ssea guiada \n\nSBF Solu\u00e7\u00e3o corporal simulado  \n\nSEM Microscopia Eletr\u00f4nica de Varredura \n\nXRD Difra\u00e7\u00e3o de raios X \n\nhttp://www.linguee.com.br/portugues-ingles/traducao/espectroscopia+no+infravermelho+por+transformada+de+fourier.html\nhttp://www.linguee.com.br/portugues-ingles/traducao/espectroscopia+no+infravermelho+por+transformada+de+fourier.html\n\n\n  \n\n\n\nSUM\u00c1RIO \n\nCAP\u00cdTULO I ....................................................................................... 25 \n\n1 INTRODU\u00c7\u00c3O ................................................................................ 27 \n\nCAP\u00cdTULO II ...................................................................................... 31 \n\n2 ARTIGO 1 EM INGL\u00caS ................................................................. 33 \n\n2.1 INTRODUCTION ........................................................................... 34 \n\n2.2 ORGANIC AGENTS INCORPORATED INTO BIOACTIVE \n\nGLASS .................................................................................................. 36 \n\n2.3 BIOACTIVE GLASS AS AN ANTIBIOTIC DELIVERY SYSTEM\n\n ............................................................................................................... 38 \n\n2.4 MULTIFACTORIAL ASPECTS INFLUENCING BIOACTIVE \n\nGLASS TO EMBED BIOFILM INHIBITORS .................................... 43 \n\n2.5 CONCLUSIONS AND OUTLOOK ............................................... 45 \n\n2.6 REFERENCES ................................................................................ 46 \n\n3 ARTIGO 2 EM INGL\u00caS ................................................................. 55 \n\n3.1 INTRODUCTION ........................................................................... 56 \n\n3.2 MATERIALS AND METHODS .................................................... 57 \n\n3.3 RESULTS ....................................................................................... 61 \n\n3.4 DISCUSSION ................................................................................. 70 \n\n3.5 CONCLUSION ............................................................................... 72 \n\n3.6 REFERENCES ................................................................................ 73 \n\n4 ARTIGO 3 EM INGL\u00caS ................................................................. 79 \n\n4.1 INTRODUCTION ........................................................................... 80 \n\n4.2 MATERIALS AND METHODS .................................................... 82 \n\n4.3 RESULTS ....................................................................................... 85 \n\n4.4 DISCUSSION ................................................................................. 92 \n\n4.5 CONCLUSION ............................................................................... 95 \n\n4.6 REFERENCES ................................................................................ 96 \n\nCAP\u00cdTULO III .................................................................................. 105 \n\n5 CONSIDERA\u00c7\u00d5ES FINAIS ........................................................ 107 \n\n6 REFER\u00caNCIAS ............................................................................. 109 \n\n\n\n \n\n\n\n25 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO I \n\n  \n\n\n\n26 \n\n  \n\n\n\n27 \n\n1 INTRODU\u00c7\u00c3O \n\nNo ano 2012, foi estimado que nos Estados Unidos mais de meio \n\nmilh\u00e3o de pacientes foram submetidos a cirurgias de enxerto \u00f3sseo por \n\nano, representando um custo acima de 2,5 bilh\u00f5es de d\u00f3lares anuais. \n\nEspera-se que para o ano 2020 este n\u00famero de pacientes seja o dobro \n\ndevido ao aumento de expectativa de vida da popula\u00e7\u00e3o mundial \n\n(AMINI; LAURENCIN; NUKAVARAPU, 2012).  Al\u00e9m do referido, o \n\nosso \u00e9 o segundo tecido mais transplantado no mundo depois do sangue \n\n(JONES, 2013). \n\nEm decorr\u00eancia do mencionado, a engenharia tecidual se encontra \n\nconstantemente pressionada pela extensa demanda de cirurgias de \n\nenxertia \u00f3ssea. Na \u00e1rea bucal e maxilofacial, procedimentos de enxerto \n\n\u00f3sseo para o reparo e regenera\u00e7\u00e3o dos tecidos s\u00e3o utilizados \n\nfrequentemente. Por conseguinte, a procura para desenvolver um \n\nbiomaterial ?ideal? para substituir os tecidos \u00f3sseos \u00e9 um tema de \n\ngrande interesse e v\u00e1rios anos de pesquisa.   \n\nAtualmente, os enxertos de origem aut\u00f3gena removidos de um \n\nleito doador do pr\u00f3prio paciente, s\u00e3o considerados o ?padr\u00e3o ouro? da \n\nenxertia por ter as caracter\u00edsticas desejadas de osteoindu\u00e7\u00e3o e \n\nosteocondu\u00e7\u00e3o. No entanto, a alta demanda de procedimentos de \n\nenxertia na regi\u00e3o oral dificulta a utiliza\u00e7\u00e3o de osso de origem aut\u00f3gena \n\nde todos os enxertos devido a fatores limitantes como a necessidade de \n\numa \u00e1rea doadora com um volume apropriado, envolvimento de um \n\nprocedimento cir\u00fargico adicional e aumento da morbidade do paciente \n\npor ser submetido a um maior n\u00famero de interven\u00e7\u00f5es. Por outro lado, \n\nos aloenxertos, removidos e transplantados entre indiv\u00edduos de uma \n\nmesma esp\u00e9cie com caracter\u00edsticas gen\u00e9ticas diferentes, j\u00e1 foram mais \n\nutilizados no passado. Atualmente s\u00e3o conhecidas desvantagens como a \n\nreabsor\u00e7\u00e3o precoce, potencial de transmiss\u00e3o de prote\u00ednas antig\u00eanicas e \n\ndoen\u00e7as infecciosas e a necessidade de um banco de ossos. Por este \n\nmotivo, a engenharia tecidual tem desenvolvido por v\u00e1rios anos diversos \n\nmateriais met\u00e1licos, cer\u00e2micos e polim\u00e9ricos a fim de substituir os \n\ntecidos \u00f3sseos perdidos, considerando que a utiliza\u00e7\u00e3o desses materiais \n\ndepende de propriedades essenciais como a biocompatibilidade, \n\nbioatividade, estabilidade f\u00edsica e qu\u00edmica e propriedades mec\u00e2nicas \n\nsimilares aos tecidos perdidos. Assim, os principais materiais \n\nalopl\u00e1sticos cer\u00e2micos que t\u00eam sido desenvolvidos a fim de ter as \n\ncaracter\u00edsticas mencionadas s\u00e3o a hidroxiapatita, o beta fosfato tric\u00e1lcio, \n\no fosfato de c\u00e1lcio bif\u00e1sico e os biovidros ativos (CRUZ et al., 2006). \n\nNo entanto a procura do biomaterial ?ideal? para substituir o tecido \n\n\n\n28 \n\n\u00f3sseo \u00e9 um constante desafio que a engenharia tecidual enfrenta \n\natualmente, j\u00e1 que ainda n\u00e3o existe um biomaterial com as propriedades \n\nbiol\u00f3gicas do tecido aut\u00f3geno e que contenha biomol\u00e9culas capazes de \n\ninduzir a forma\u00e7\u00e3o \u00f3ssea (JONES, 2013).  \n\nAl\u00e9m dos fatores biol\u00f3gicos, qu\u00edmicos e mec\u00e2nicos de um \n\nbiomaterial ?ideal?, a capacidade antibacteriana e antibiofilme \u00e9 uma \n\ncaracter\u00edstica adicional desejada e requerida nos procedimentos de \n\nenxertia \u00f3ssea. A incid\u00eancia de infec\u00e7\u00e3o \u00f3ssea p\u00f3s-operat\u00f3ria \u00e9 \n\nconsider\u00e1vel e \u00e9 uma complica\u00e7\u00e3o frequente das cirurgias orais \n\nenvolvendo enxertia \u00f3ssea (EL-KADY et al., 2012b; XIE et al., 2009).  \n\nAs bact\u00e9rias organizadas no biofilme  s\u00e3o as protagonistas de 80% das \n\ninfec\u00e7\u00f5es humanas (DAVIES, 2003). De modo que a utiliza\u00e7\u00e3o de \n\nantibi\u00f3tico terapia \u00e9 frequente para a preven\u00e7\u00e3o de infec\u00e7\u00f5es secund\u00e1rias \n\nneste tipo de procedimentos, no entanto o antibi\u00f3tico n\u00e3o \u00e9 sempre \n\ncapaz de induzir um efeito efetivo no tecido \u00f3sseo infectado j\u00e1 que n\u00e3o \n\natua de forma local e atua em uma \u00e1rea com pouca vasculariza\u00e7\u00e3o. \n\nAdicionalmente,  as bact\u00e9rias organizadas em biofilme s\u00e3o mil vezes \n\nmais resistentes ao antibi\u00f3tico comparadas com as bact\u00e9rias planct\u00f4nicas \n\n(DAVIES, 2003; GALARRAGA-VINUEZA et al., 2017). Assim, um \n\nbiomaterial com propriedades antibiofilme seria capaz de atuar de \n\nmaneira mais eficaz e local na \u00e1rea enxertada infectada.  No entanto, \n\npoucos materiais t\u00eam demostrado capacidade antibacteriana e \n\nantibiofilme consistente. \n\n O biovidro ativo desenvolvido no ano 1969, aplicado em mais de \n\num milh\u00e3o de pacientes no mundo para procedimentos de regenera\u00e7\u00e3o \n\n\u00f3ssea (HOPPE; G\u00dcLDAL; BOCCACCINI, 2011; JONES, 2013), \u00e9 um \n\nbiomaterial capaz de inibir o crescimento bacteriano atrav\u00e9s da libera\u00e7\u00e3o \n\nde \u00edons que elevam o pH do meio e criam um ambiente pouco favor\u00e1vel \n\npara o crescimento bacteriano (ALLAN; NEWMAN; WILSON, 2002; \n\nKRISHNAN; LAKSHMI, 2013). Esta caracter\u00edstica ambiciosa do \n\nbiovidro, al\u00e9m das suas outras propriedades de promover a osteog\u00eanese \n\ne angiog\u00eanese tem posicionado o biovidro ativo como um biomaterial \n\npromissor (JONES, 2013). Certamente, a capacidade antibacteriana do \n\nbiovidro ativo \u00e9 de fundamental import\u00e2ncia por ter um efeito local \n\ndesejado no leito cir\u00fargico (BELLANTONE; COLEMAN; HENCH, \n\n2000; HENCH, 2006). Entretanto, o efeito antibiofilme dos biovidros \n\nativos n\u00e3o foi elucidado nem confirmado nos \u00faltimos estudos \n\n(GALARRAGA-VINUEZA et al., 2016), raz\u00e3o pela qual diversas \n\npesquisas t\u00eam mudado a composi\u00e7\u00e3o e a estrutura do biovidro ativo a \n\nfim de conseguir uma maior capacidade antibacteriana e antibiofilme \n\n(HUM; BOCCACCINI, 2012). Diferentes avan\u00e7os t\u00eam sido \n\n\n\n29 \n\napresentados como a incorpora\u00e7\u00e3o de agentes antibacterianos na \n\ncomposi\u00e7\u00e3o qu\u00edmica ou estrutura f\u00edsica do biovidro ativo. Deste modo, \n\ncompostos de prata, c\u00e9ria, sel\u00eanio, fl\u00faor, entre outros t\u00eam sido \n\nadicionados na f\u00f3rmula qu\u00edmica do biovidro ativo a fim de melhorar sua \n\ncapacidade antibacteriana e antibiofilme (MALAVASI et al., 2012; \n\nSTEVANOVI? et al., 2015; XU et al., 2015). Por outro lado, a \n\ntecnologia nano tem mudado a estrutura deste material adicionando \n\nsurfactantes (XIA; CHANG, 2006) na sua f\u00f3rmula para induzir a \n\nforma\u00e7\u00e3o de poros convertendo assim o material num biovidro ativo \n\nmesoporoso que tem a capacidade de incorporar nos seus nano poros \n\nsubst\u00e2ncias antibacterianas e antibiofilmes como antibi\u00f3ticos, nano \n\npart\u00edculas bioativas e compostos naturais org\u00e2nicos (EL-GHANNAM; \n\nAHMED; OMRAN, 2005; JIA et al., 2010; PRABHU et al., 2014; XIA \n\net al., 2008).  \n\nConsiderando que ainda n\u00e3o existe um consenso, assim como \n\nestudos suficientes esclarecendo que tipo de compostos t\u00eam efeito \n\nantibiofilme, o objetivo do presente estudo foi desenvolver e avaliar a \n\ncapacidade antibiofilme do biovidro ativo 58S incorporando compostos \n\norg\u00e2nicos e inorg\u00e2nicos na sua estrutura qu\u00edmica e f\u00edsica.  De tal modo, \n\na hip\u00f3tese do presente estudo \u00e9 que a incorpora\u00e7\u00e3o de agentes \n\ninorg\u00e2nicos e org\u00e2nicos no biovidro ativo potencializar\u00e1 seu efeito \n\ninibit\u00f3rio do biofilme oral. \n\nPor conseguinte, o presente manuscrito est\u00e1 divido em tr\u00eas partes, \n\nsendo a primeira uma revis\u00e3o da literatura da incorpora\u00e7\u00e3o de agentes \n\nantibacterianos e antibiofilmes no biovidro ativo, a segunda descrevendo \n\na capacidade antibiofilme do biovidro ativo modificado com brometo de \n\nc\u00e1lcio e a terceira mostrando o desenvolvimento e bioatividade do \n\nbiovidro ativo mesoporoso incorporando compostos de origem natural.   \n\n  \n\n\n\n30 \n\n  \n\n\n\n31 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO II \n\n  \n\n\n\n32 \n\n  \n\n\n\n33 \n\n2 ARTIGO 1 EM INGL\u00caS \n\nO artigo a seguir foi publicado na revista cient\u00edfica Journal of \n\nBiomedical materials research: part A. Fator de impacto: 3.263. Qualis: \n\nA1 \n\nAnti-biofilm properties of bioactive glasses embedding organic \n\nactive compounds  \n\nM.E. Galarraga-Vinueza\n1\n, J. Mesquita-Guimar\u00e3es\n\n2\n, R. S. Magini\n\n1\n, J. C. \n\nM. Souza\n1,2\n\n, M. C. Fredel\n2\n, A. R. Boccaccini\n\n3* \n\n1\nCenter for Education and Research on Dental Implants (CEPID), Post-\n\nGraduation Program in Dentistry (PPGO), Department of Dentistry \n\n(ODT), Federal University of Santa Catarina(UFSC), Florian\u00f3polis/SC, \n\n88040-900, Brazil \n2\nCeramic and Composite Materials Research Group (CERMAT), \n\nFederal University of Santa Catarina, Florian\u00f3polis 88040-900, Brazil \n3\nInstitute of Biomaterials, Department of Materials Science and \n\nEngineering, University of Erlangen-Nuremberg, 91058 Erlangen, \n\nGermany\n \n\n*Corresponding author: A.R. Boccaccini, aldo.boccaccini@ww.uni-\n\nerlangen.de \n\nAbstract:  \n\nBioactive glasses (BGs) are promising materials for bone repair due to \n\ntheir desirable properties such as osteoconductivity, biodegradability, \n\nangiogenic potential, and antibacterial activity. Ionic dissolution \n\nproducts from bioactive glasses increase the medium pH inhibiting \n\nsurrounding bacteria proliferation. The activity of BGs against biofilm \n\nformation has been enhanced by incorporating organic antibacterial \n\ncompounds. The aim of this review was to summarize evidence in \n\nliterature which assesses the efficacy of antibacterial and anti-biofilm \n\ncompounds embedded in bioactive glasses to prevent peri-implant \n\ninfection during bone healing. A PubMed bibliographical research was \n\ncarried out including articles published in the last 20 years. Most \n\nprevious studies evaluated antibacterial efficiency in planktonic cultures \n\nbut did not investigate biofilm inhibition, underestimating biofilm \n\nclinical relevance. Multifactorial features such as biocompatibility of \n\nembedded compounds, receptor site characteristics, and drug delivery \n\n\n\n34 \n\nefficiency have been found to influence the bioactive glass capability of \n\nacting both as an anti-biofilm agent and as a bone repairing biomaterial. \n\nAccordingly, further in vitro and in vivo studies are required to select \n\nthe most promising anti-biofilm agents which should be incorporated \n\ninto bioactive glasses to counteract biofilm proliferation, without \n\ninducing toxic effects on human cells, and with the added functionality \n\nof promoting bone regeneration.  \n\nKey Words: bioactive glass, mesoporous materials, antibacterial \n\ncompounds, anti-biofilm activity, drug delivery system \n\n2.1 INTRODUCTION \n\nBone is the second most transplanted tissue in surgical procedures \n\nworldwide with bone tissue engineering being investigated as a realistic \n\nalternative for bone healing [1]. Bone tissue engineering often relies on \n\nan engineered scaffold acting as a temporary extracellular matrix to \n\nsupport and deliver cells [2]. Bioactive glasses (BGs) involve a group of \n\ninorganic biomaterials discovered in the late 1960s that have been \n\napplied in bone repair due to their bioactivity, osteogenic, and \n\nangiogenic potential, biodegradability, and osteoconductivity [3]. BGs \n\nstimulate diverse biologic responses in contact with physiological fluids, \n\nsuch as the development of a carbonated hydroxyl-apatite (CHA) \n\nsurface layer that is comparable to the mineral phase of bone and acts as \n\nan interface to enhance the attachment of bone cells. BGs also possess \n\nantibacterial potential due to their high surface reactivity and ion release \n\ncapability [4, 5] causing high aqueous pH values in the surrounding \n\ntissues; however, such antibacterial effect has been reported to be \n\nrestricted to certain planktonic bacteria [6\u201311]. Consequently, various \n\napproaches have been put forward for the incorporation of additional \n\nantibacterial compounds into BG compositions to enhance antibacterial \n\nand anti-biofilm activity, this being the subject of the present review.  \n\nBiofilm is a multi-species agglomerate of microbial cells \n\nenclosed in a well-organized extracellular polymeric substance (EPS) \n\nmatrix that adheres to soft and hard surfaces. The EPS matrix allows \n\ngenetic information exchange and chemical signaling between microbial \n\ncells through a mechanism known as quorum sensing. Biofilms act as a \nbiological barrier against therapeutic agents and host immune cells; \n\nretaining also nutrients from the environment [12,14]. Biofilms \n\ncontaining pathogenic species are reported to cause over 80% of human \n\ninfections [12\u201314]. Oral biofilms adhere to different surfaces of \n\nprostheses, implants, mucosa, teeth, and bone. Biofilm formation is a \n\n\n\n35 \n\ngradual process consisting of four distinct stages [13\u201315]: (a) acquired \n\npellicle formation; (b) primary (early) colonization; (c) secondary \n\ncolonization/ co-aggregation; and (d) mature biofilm establishment. The \n\nearly colonization begins through binding primary bacteria to a \n\nconditioning film composed of glycoproteins, water and nutrients, that is \n\npreviously established in the mouth. The first adherent oral bacteria \n\n(Streptococcus sanguinis, S. oralis, S. gordonii, S. mitis, Actinomyces \n\nnaeslundii, Capnocytophagaochraceae, S. mutans and S. sobrinus) are \n\nweakly and reversibly linked to glycoproteins named by adhesins, \n\nalthough they may remain and proliferate, starting the phenomena of \n\nmicrobial co-aggregation. Steptococcus species represent 60\u201380% of all \n\nprimary colonizers. Such coaggregation is mediated by metabolic and \n\ngenetic exchange known as quorum sensing. The secondary colonization \n\noccurs within 3\u20135 days after the beginning of the early colonization. In \n\nthis process, the microorganisms start to multiply and to co-aggregate \n\nwith partner species leading to the biofilm structural organization. \n\nMicroorganisms organized in biofilms achieve a strong adherence to \n\noral surfaces leading to a maturation process within 2\u20133 weeks [12\u201315]. \n\n Previous studies have described that biofilms are about one \n\nthousand times more resistant to antibiotic therapy compared to free \n\nfloating planktonic bacteria [12, 15]. In addition, studies have described \n\nthat conventional systemic antibiotic therapy is not as effective as \n\nexpected to eradicate bone infection because antibiotics do not act \n\nlocally in septic areas and they may induce side effects in patients \n\n[13,16]. In the last decade, sol-gel derived mesoporous bioactive glasses \n\n(MBGs) have been developed with the purpose of becoming carriers for \n\ntherapeutic agents acting as drug delivery systems [17\u201320]. \n\nConsequently, MBGs are advantageous candidates for both bone repair \n\nand peri-implant infection treatment since they combine unique \n\nproperties to stimulate bone growth and prevent bacteria proliferation.  \n\nThe present review assesses antibacterial and antibiofilm efficacy \n\nof BG carriers embedding organic compounds focusing on multifactorial \n\nparameters that can control antibacterial effects during bone healing. A \n\nPubMed electronic search including articles published in the last 20 \n\nyears was performed using the following combination of key words and \n\nMeSH terms: ?bioactive glass? or ?Bioglass? and ?antibacterial? or \n\n?anti-infective? or ?antibiotics? or ?antibacterial? or ?biofilm \n\ninhibition?. The selection criteria identified papers describing in vitro \n\nand in vivo studies, thus only articles that evaluated specifically \n\nantibacterial or anti-biofilm effects of bioactive glasses embedding \n\nantibacterial compounds were reviewed and discussed. The present \n\n\n\n36 \n\narticle is not intended to be comprehensive in terms of the number of \n\nstudies included; it is rather a discussion article containing the relevant \n\ninformation found in key publications to provide the reader with initial \n\npoints for further analysis.  \n\n2.2 ORGANIC AGENTS INCORPORATED INTO BIOACTIVE \n\nGLASS  \n\nIn the last years, several studies have shown proper antibacterial \n\nproperties achieved by different formulations of bioactive glasses \n\nincorporating several oxides [21\u201323] and the effects of biologically \n\nactive ions on bone tissue engineering have been discussed in literature \n\n[24]. In addition, commercial products based on bioactive glass (melt-\n\nderived, composition SiO2 53%, Na2O 23%, CaO 20%, P2O5 4%) are \n\nbeing successfully applied in the clinic to treat osteomyelitis [25] and \n\nthe application of BGs to treat bone infections by the effect of pH \n\nincrease is well demonstrated in literature [4,6,26,27]. Recent studies \n\ndescribe the incorporation of triclosan 28 into BG considering that this \n\ncompound has already been applied in mouthwash solutions for clinical \n\nconsiderations involving biofilm-induced infections. Xu et al. reported \n\nin vitro antibacterial effects of 45S5 BG embedding triclosan against \n\ncariogenic S. mutans biofilm [29]. This study assessed anti-biofilm \n\nactivity by pouring BG powders incorporating triclosan into wells \n\ncontaining S. mutans biofilm plaques that had undergone 6, 12, and 24 h \n\nof growth conditions. After 10 min of exposure, each coverslip \n\ncontaining biofilm was washed with PBS and centrifuged in saline \n\nsolution. Subsequently, S. mutans biofilm was detached from the cover \n\nslips and then incubated in agar plates for 48 h at 37?C, simulating oral \nconditions. Biofilm viable colonies were counted and observed using a \n\nstereomicroscope and scanning electron microscope. The study showed \n\nadditive anti-biofilm effects when BG was combined with triclosan. \n\nPertinently, this previous study focused on the assessment of anti-\n\nbiofilm activity rather than antibacterial effect against planktonic \n\ncultures. However, this broad-spectrum antibacterial agent is \n\nhydrophobic and can accumulate in human fatty tissues, breast milk, \n\nurine, and serum [30]. Furthermore, that synthetic organic agent has \n\nbeen reported to cause endocrine disruption in mammals, affecting the \n\nthyroid hormone reproduction and its homeostasis, [31] so that further \n\nresearch on triclosan containing BGs will have to investigate possible \n\nnegative effect of its use.  \n\n\n\n37 \n\nNatural organic compounds derived from medicinal plants known \n\nas phytotherapeutics can promote both antibacterial and anti-\n\ninflammatory activity [32]. The scientific interest in natural active \n\ncompounds has increased for biomedical applications, since they are \n\nwell-known health-promoting agents and produce minimum side effects. \n\nEssential oils derived from plants have numerous desirable properties \n\nbeing antibacterial, antiviral, antifungal, and having insecticide potential \n\n[33]. Regarding natural organic compounds as favorable antibacterial \n\nagents in combination with BGs, Prahbu et al. [34] studied the in vitro \n\nantimicrobial effect of BGs of composition (58SiO2-33CaO-9P2O5) \n\nincorporating neem plant (Azadirachta indica) leaf powder, a natural \nantiviral and antibacterial compound against a broad spectrum of \n\nbacteria [35]. BG nanoparticles (NPs) doped with neems leaf powder \n\nwere analyzed by using Kirby-Bauer disc diffusion method and \n\nexhibited considerable antimicrobial activity against S. aureus and E. \n\ncoli cultures. Additionally, neem doped BG NPs demonstrated superior \nantibacterial properties against Gram-positive and Gram-negative \n\nbacteria in comparison to those recorded for silver doped or pure BG \n\nNPs. Besides the beneficial antibacterial effect, neem-doped BG \n\nnanoparticles were analyzed by MTT assay and exhibited reduced \n\ncytotoxic effects. Results of that study established that neem doped BG \n\nwas a biocompatible and potent antibiofilm agent for tissue engineering \n\napplications [34].  \n\nAn alternatiive approach toward incorporating natural organic \n\ncompounds into BGs was performed by Bonfim et al. [36]. In this study, \n\nBrazilian red and green propolis were incorporated into BGs of \n\ncomposition (SiO2)0.80(P2O5)0.04(CaO)0.16. Propolis, a natural non-\n\ntoxic beehive agent found in honeycombs, has antifungal and antiviral \n\nproperties as well as antibacterial activity against a wide range of cocci \n\nand Gram-negative rods [37]. Propolis solution was added during the \n\nBG sol-gel synthesis to obtain specimens for antimicrobial assays. The \n\nin vitro study reported growth inhibition on the following pathogenic \n\nspecies: S. aureus, E. faecalis, S. mutans, P. intermedia, F. nucleatum, \n\nP. gingivalis, and A. actinomycetemcomitans [36]. Accordingly, propolis \nis considered an antibacterial natural compound of high potential for \n\nfuture developments given its ability to inhibit bacterial adherence, \n\nprevent biofilm accumulation, and to reduce virulence factors of S. \nmutans [38]. Also, Propolis has been evaluated in previous studies \n\nshowing a noncytotoxic nature [39, 40]. Grenho et al. [41] reported that \n\npropolis had antibacterial effectiveness and exhibited bioactive \n\n\n\n38 \n\ncharacteristics such as stimulation of fibroblast migration, high cell \n\nmetabolic activity, and absence of cell membrane damage. \n\n Despite the success reported by some investigations mentioned \n\nabove, organic compounds, especially natural derived agents like \n\nphytotherapeutics have not been largely explored to date in combination \n\nwith BGs. Since BGs have the ability to incorporate both hydrophilic \n\nand hydrophobic groups in their structures, in vitro and in vivo studies \n\ninvolving natural organic compounds bound to BGs are expected to \n\nincrease. Considering that various nature derived agents have reduced or \n\nnon-cytotoxic effects [32\u201334,40] future investigations involving also \n\nclinical trials should be performed to identify the advantages and \n\nsynergies brought by the combination of natural organic compounds and \n\nBGs to avoid peri-implant infections.  \n\n2.3 BIOACTIVE GLASS AS AN ANTIBIOTIC DELIVERY \n\nSYSTEM  \n\nIn the last 15 years, BGs have been increasingly considered as \n\nvehicles for the local delivery of drugs, growth factors, and antibiotics \n\n[17\u201319, 42\u201345]. Tissue engineering approaches using BG scaffolds, \n\nwhich include a therapeutic drug or antibiotic delivery capability are \n\nbased on multifunctional scaffolds, which are capable of releasing \n\ntherapeutic substances against microbial infections in a controlled \n\nmanner during the process of tissue repair [17, 42, 43, 45\u201348]. Systemic \n\nantibiotic therapy is not always effective to treat bone infections since \n\nthere is vascular insufficiency and antibiotics may not arrive to infected \n\nareas through the blood stream. On systemic therapy, antibiotic \n\nbiomolecules can be inactivated in the blood stream and may have no \n\neffect where they are needed at the implanted sites [8, 17]. In cases of \n\nbone repair procedures, there is a high incidence of infection and \n\ninflammatory response caused by host immune reactions. Attempting to \n\nsolve implantation site complications, BG carriers with well-organized \n\nmesoporous structures are developed [18\u201320, 44, 45] which exhibit \n\nadjustable pore diameter and high surface area where antibiotics can be \n\nencapsulated for their controlled delivery. A previous study involving \n\nMBG reported a continuous release of gentamicin for six days inhibiting \n\nbacterial adhesion and biofilm formation of S. aureus and S. epidermis, \n\nwhich are prevalent species at implant infections [44].  \n\nSimilarly, Xie et al. [46] preformed an in vivo study to evaluate \n\nthe antibacterial effect of loaded gentamicin pellets composed of \n\nchitosan and borate-based BG. A bone tissue infection (osteomyelitis) \n\n\n\n39 \n\nassociated to Gram-negative bacilli was induced in a rabbit tibia model \n\nand then treated by the application of gentamicin-loaded BG pellets. \n\nResults from microbiological, radiographical, and histological assays \n\nstated an eradication of 81.82% infected cases. That study indicated that \n\ngentamicin-loaded BG pellets are attractive materials for osteomyelitis \n\ntreatment. In addition, related in vivo studies performed by Nandi et \n\nal.[47] reported control of bone resorption in experimental osteomyelitis \n\nand consequent formation of lamellar bone by using cefuroxime axetil \n\n(CFA)-loaded MBG.  \n\nThe results of several studies have thus indicated that local \n\nantibiotic release from MBGs can be a solution to treat bone infection. \n\nVarious antibiotics such as carbeinicillin, [48] ciprofloxacin, [49] \n\ntetracycline hydrochloride (TCH), [50,51] vancomycin, [52,53] and \n\nteicoplanin [54] have been incorporated into BGs, as summarized in \n\nTable I. Nevertheless, biofilm infections at receptor sites are resistant to \n\nseveral antibiotics due to the presence of pathogenic species in well-\n\norganized extracellular matrices [12]. Rastegar et al. [55] reported that \n\nP. aureginosa, a specie associated to the formation of biofilm on \n\nimplanted devices, was resistant to carbenicillin, cotrimoxazole, \n\nceftizoxime, gentamicin, and tetracycline in 95% of the cases of wound \n\ninfections. On a comparative study of antibiotic resistance between \n\nplanktonic bacteria and biofilm cultures, Olson et al. [13] found that the \n\nminimum biofilm inhibitory concentrations of cloxacillin, amoxicillin, \n\ngentamicin, ampicillin, tetracycline, penicillin G, and ceftiofur were not \n\nable to eradicate biofilms formed by A. pyogenes, S. aureus, S. hyicus, S. \n\nagalactiae, C. renale, and C. pseudotuberculosis. However, it was \n\nshown that planktonic cultures were susceptible to several antibiotics. \n\nConsidering the clinical relevance of biofilm resistance to antibiotics, \n\nincorporating anti-biofilm compounds rather than antibiotics into BGs \n\nrepresents a more effective approach that should be explored more \n\nintensively in future. Further studies are required to understand and \n\ncharacterize factors involved in biofilm growth, microbial gene \n\nexchange, and bacteria communication to develop new anti-infective \n\nchemotherapies, which can involve BGs loaded with antibiofilm agents. \n\n\n\n40 \n\nTable I. Summary of Relevant Studies on Antibiotic-Loaded Bioactive Glasses to Prevent Infection \n\nStudy/ Experimental \n\ndesign \n\nBG  composition  Loaded Antibiotic \nOutcome \n\nAntibacterial Effect Targeted \n\nbacterias \n\nLi et al. (LI et al., \n\n2013) \n\nIn vitro \n\nMesoporous BG * Gentamicin Inhibition of bacterial adhesion and \n\nbiofilm formation \n\nS. aureus  \n\nS. epidermis \n\nXie et al. (XIE et al., \n\n2009a) \n\nIn vitro/ in vivo \n\n(osteomyelitis \n\ninduced in an animal \n\nmodel) \n\nPellets of chitosan-\n\nbonded with borate BG \n\n[mol%] 6Na2O,8K2O, 8 \n\nMgO, 22 CaO, 54 B2O3, \n\n2P2O5 \n\nGentamicin  In vitro:  \n\nInhibition of bacterial growth \n\nIn vivo:  \n\n6 weeks after implantation, 9 out of \n\n11 rabbits were \n\nnegative for E. coli by culture \n\nanalysis. \n\nEradication of 81.82% of bone \n\ninfection cases demonstrated by \n\nradiographic, histopathologic, and \n\nmicrobiological examinations. \n\nE. coli  \n\n Miola et al. (MIOLA \n\net al., 2013) \n\nIn vitro \n\nBG [mol%] \n\n45SiO2,3P2O5, 26CaO, \n\n7MgO, 15Na2O, 4K2O \n\nCarbenicillin  Samples released an antibiotic \n\namount considerably higher than S. \n\naureus MIC (minimum inhibitory \n\nconcentration) of carbenicillin. \n\nN.A.  \n\nMabrouk et al. \n\n(MABROUK et al., \n\n2014) \n\nIn vitro \n\nComposite scaffolds of \n\npolyvinyl alcohol and \n\nquaternary 46S6 BG \n\n[mol%] 46SiO2, 24 CaO, \n\n24Na2O, 6P2O5 \n\nCiprofloxacin  N.A. N.A. \n\nRivadeneira et al. BG 45S5 Tetracycline Bacterial cell growth inhibition, 4 staphylococci \n\n\n\n41 \n\n(RIVADENEIRA et \n\nal., 2014) \n\nIn vitro \n\nnanoparticles/collagen \n\ncomposites [mol%] \n\n45SiO2, 24Na2O, \n\n24CaO, 6P2O5 \n\nhydrochloride \n\n(TCH)   \n\nantibacterial efficacy was similar for \n\nall TCH concentrations: 0.05, 0.20, \n\n0.35 mg ml \n-1\n\n \n\nstrains: S. aureus \n\nATCC29213, \n\nATCC25923, \n\nATCC6538P and \n\nS. epidermidis \n\nATCC12228. \n\nDomingues et al. \n\n(DOMINGUES et al., \n\n2004) \n\nIn vitro/ In vivo \n\n(animal model) \n\nBG [mol%] 80SiO2, 16 \n\nCaO, 4P2O5 \n\n \n\n- Tetracycline \n\nhydrochloride (BT) \n\n-Complex formed \n\nby tetracycline and \n\nbeta-cyclodextrin \n\n(BTC) \n\n-A significant bacteriostatic activity \n\nwas found with BT and BTC glasses. \n\n-Cyclodextrin slowed down the \n\nrelease of tetracycline for a long \n\nperiod of time. \n\n-Bactericidal activity increased when \n\nBG was loaded with tetracycline \n\nA. \n\nactinomycetemco\n\nmitans \n\nRivadeneira et \n\nal.(RIVADENEIRA et \n\nal., 2015) \n\nIn vitro \n\nAgar\u2013gelatin (AG) 45S5 \n\nBG microparticles \n\ncomposites \n\n[mol%] 45SiO2, \n\n24Na2O, 24CaO, 6P2O5 \n\nVancomycin \n\nhydrochloride (VC)  \n\n-Bacterial cell viability for S. aureus \n\nATCC6538 was considerably \n\ninhibited  \n\nafter 24 and 48h of incubation. \n\n-AG-BG samples loaded with VC \n\ndid not reduce the number of \n\nbacteria below 10\n5\n \n\ncfu (colony forming units) \n\nml\n?1\n\n \n\n3 staphylococcus \n\nstrains:  \n\nS. aureus \n\nATCC29213, S. \n\naureus \n\nATCC6538, and  \n\nS. epidermidis \n\nATCC12228.  \n\n  \n\n\n\n42 \n\nYao et al. (YAO et al., \n\n2013) \n\nIn vitro \n\n45S5 BG scaffolds \n\ncoated with \n\npolycaprolactone and \n\nvancomycin-loaded \n\nchitosan, [mol%] \n\n45SiO2,24Na2O, 24CaO, \n\n6P2O5 \n\nVancomycin  N.A. N.A. \n\nJia et al. (JIA et al., \n\n2010) \n\nIn vitro/in vivo \n\n(osteomyelitis \n\ninduced in an animal \n\nmodel) \n\nBorate BG and chitosan \n\ncomposite [mol.%] \n\n6Na2O, 8K2O, 8MgO, \n\n22CaO, 54B2O3, 2P2O5 \n\nTeicoplanin  \n\n(TBGC) \n\nIn vivo: efficient therapeutic effect \n\nwas revealed in animals implanted \n\nwith TBGC pellets, showing an \n\ninferior positive rate of MRSA \n\nculture. \n\nMethicillin-\n\nresistant S. \n\naureus \n\n(MRSA) \n\n* BG composition is not specified in the study. N.A.: not applied, study has not performed specific antibacterial tests\n\n\n\n43 \n\n2.4 MULTIFACTORIAL ASPECTS INFLUENCING BIOACTIVE \n\nGLASS TO EMBED BIOFILM INHIBITORS  \n\nBiofilms in infected implanted tissues have an unquestionable \n\nclinical significance; for that reason, clinical guidelines involving \n\neffective protocols and superior biomaterials must be established for \n\ninfection management. It is remarkable that the majority of studies \n\ndealing with antibacterial materials does not mention or consider in \n\ndetail antibacterial activity. In general, studies show proper antibacterial \n\nactivity against planktonic bacteria. Those studies suggest that a \n\n?proper? antibacterial activity is necessary for should be considered for \n\nfuture medical applications in bone infection therapy [4, 56]. However, \n\nit can be considered a controversial issue if the antibacterial effect \n\nachieved in those studies is sufficiently effective to treat human \n\ninfections [57]. Other previous studies have evaluated anti-biofilm \n\nactivity against mono-species biofilm formation [29, 58]. Perez-Tanoira \n\net al. for example, reported that S53P4 BG prevented bacterial and \n\nbiofilm adhesion, however this study; nevertheless, this study tested \n\nsolely staphylococcal biofilm inhibition. Other recent studies have tested \n\nanti-biofilm properties of compounds against multi-species biofilms. \n\nBortolin et al [59] revealed that S53P4 BG was able to reduce biofilm \n\ncomposed of S. epidermis, A. baumanii, and K. pneumoniae. \nFurthermore, Drago et al. [60] reported that S53P4 BG revealed a \n\nrelevant biofilm inhibition effect on S. aureus and P. aureginosa. In \n\nprinciple, even if studies that analyze antibiofilm effects are reliable; \n\nincreased efforts involving in vivo studies are needed to simulate \n\nrealistic human infection conditions.  \n\nHuman body infections, especially bone infections, are complex, \n\nand cannot be controlled by antibacterial effects solely. In general, bone \n\ninfections are hard to treat due to diverse biological factors, notably \n\nvascular insufficiency, where systemic antibiotics and host immune cells \n\nare not able to reach the infected area through the blood stream.16 In \n\naddition, bone infections induced by multi-species biofilm formation \n\nincrease antibiotic resistance and bacteria pathogenicity.12,15 \n\nAccordingly, bone infection treatment should focus primarily on \n\ninhibiting biofilm formation [61]. Nowadays, there are limited effective \n\ntherapies specifically targeting biofilm formation. Mechanical \n\ndebridement for infected bone removal is the most accepted clinical \n\nprocedure [16]. Therefore, if bone debridement could be complemented \n\nby the application of an efficient anti-biofilm agent, for example based \n\n\n\n44 \n\non mesoporous bioactive glasses as discussed in this review, such \n\nbiomaterial will be a promising candidate for bone infection treatment, \n\nas schematically illustrated in Figure 1. \n\n \nFigure 1. Schematic diagram showing mesoporous BG loaded with \n\nantibacterial agents applied and delivered at infected implanted receptor sites \n\nwith an acid medium to inhibit biofilm proliferation and repair bone defects. \n\nAnother factor to consider is the type of active compound \n\nembedded into the BG carrier. As mentioned above, studies have been \n\nperformed involving natural organic compounds such as essential oils \n\nand phototherapeutics as essential oils, which appear as valid \n\nalternatives for synthetic drugs [34, 36]. Consequently, new challenges \n\nhave emerged to incorporate natural derived agents into BG \n\ncompositions with the purpose of inducing antibacterial and health-\n\npromoting effects at receptor sites. Additionally, MBGs with highly \n\norganized structure have been reported to favor angiogenic and \nosteogenic responses [17, 20, 62]. For this reason, promising future \n\napproaches should consider MBG advantages and develop mechanisms \n\nto encapsulate pharmacological agents based on phytotherapeutics into \n\nwellorganized MBGs to enhance bone repair, inhibit biofilm formation, \n\nand reduce toxic effects. Indeed understanding the synergetic effects of \n\n\n\n45 \n\nthe release of both therapeutic ions and organic antibacterial agents \n\nremains a subject of high interest for future studies.  \n\nIn this context, identifying parameters that influence the \n\nperformance of MBGs as drug carriers is crucial to improve their action \n\nin infected receptor areas. Bone receptor surgical sites are inflammatory \n\nacidic areas where local acidosis increases due to the presence of \n\nbacterial metabolism byproducts like fatty acids and lactic acid \n\nproduced infiltrated neutrophils [63]. MBG based drug delivery systems \n\ncould take advantage of this acidic condition when applied on infected \n\nreceptor areas and become a pH sensitive drug delivery structure, as \n\nschematically shown in Figure 13, [64]. Previous studies have shown \n\nthat gentamicin released from MBG is pH dependent. Xia et al.64 \n\nreported MBGs as dual drug delivery systems where individual drugs \n\ncould be released at different rates depending on the pH values of the \n\nsurrounding area. Also, another study [65] established that gentamicin-\n\nloaded MBG exhibited drug release sensitive to the pH and the ionic \n\ncomposition of the surrounding medium. Consequently, significant \n\nfeatures from receptor implanted sites such as biofilm accumulation and \n\ninfiltrated inflammatory cells should be considered in forthcoming \n\nstudies to enhance the capabilities of BGs as controlled delivery systems \n\nfor anti-infective agents that can possess continuous action and efficient \n\nrelease.  \n\n2.5 CONCLUSIONS AND OUTLOOK  \n\nThe majority of the reviewed scientific literature in the field of \n\nantibacterial materials has focused on in vitro and in vivo assays in \n\nspecific models. Furthermore, most of the studies assessed antibacterial \n\nefficiency in planktonic bacteria cultures, which do not mimic a genuine \n\ninfected tissue environment. Underestimation of biofilm significance in \n\nbone infection and repair procedures is a matter of concern, since studies \n\nmay represent unrealistic conditions and they could be assessing \n\nantibacterial agents that may be inefficient or do not have the desired \n\neffects in future clinical applications. In fact, diverse multifactorial \n\nfeatures influence the bioactive glass capability of being simultaneously \n\nan antibacterial, antibiofilm, and repairing biomaterial. Such factors \n\ninvolve incorporation of different biocompatible organic compounds \n\nwith antibacterial and anti-biofilm potential, evaluation of receptor site \n\nconditions, drug delivery efficiency, and understanding synergetic \n\neffects with the intrinsic metallic ion release capability of BGs in the \n\ncontext of osteogenic and angiogenic response. The mentioned \n\n\n\n46 \n\ncharacteristics can improve BGs making them biomaterials of choice for \n\nbone infection treatment and bone repair applications. In this context, \n\nfurther comprehensive in vitro and in vivo studies applying mesoporous \n\nbioactive glass incorporating effective anti-biofilm compounds at \n\ninfected receptor sites are required.  \n\n2.6 REFERENCES  \n\n1. Quarto R, Giannoni P. Bone tissue engineering: Past-presentfuture. \n\nMethods Mol Biol 2016;1416:21\u201333. doi:10.1007/978-1-4939- \n\n3584-0_2.  \n\n2. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR. Biodegradable \n\nand bioactive porous polymer/inorganic composite scaffolds for \n\nbone tissue engineering. Biomaterials 2006;27:3413\u20133431. () doi: \n\n10.1016/j.biomaterials.2006.01.039.  \n\n3. Hench LL. Opening paper 2015- Some comments on Bioglass: \n\nFour eras of discovery and development. Biomed Glas 2015;1:1\u2013 \n\n11. doi:10.1515/bglass-2015-0001.  \n\n4. Gubler M, Brunner TJ, Zehnder M, Waltimo T, Sener B, Stark WJ. \n\nDo bioactive glasses convey a disinfecting mechanism beyond a \n\nmere increase in pH? Int Endod J 2008;41:670\u2013678. doi:10.1111/ \n\nj.1365-2591.2008.01413.x. \n\n5. Zhang D, Munukka E, Lepparanta O, Hupa L, Yl \u20ac anen H, \n\nSalonen J, \u20ac Eerola E, Viljanen MK, Hupa M. Comparison of \n\nantibacterial effect of three bioactive glasses. Key Eng Mater \n\n2006;309\u2013311 I:345\u2013\n\n348.http://www.scopus.com/inward/record.url?eid52-s2.0- \n\n33645385660&amp;partnerID540&amp;md5547b7f40cb62189e0d \n\n04ad758cffafe55.  \n\n6. Hu S, Chang J, Liu M, Ning C. Study on antibacterial effect of \n\n45S5 Bioglass. J Mater Sci Mater Med 2009;20:281\u2013286. doi: \n\n10.1007/s10856-008-3564-5.  \n\n7. Cui X, Gu Y, Li L, Wang H, Xie Z, Luo S, Zhou N, Huang W, \n\nRahaman MN. In vitro bioactivity, cytocompatibility, and \nantibiotic release profile of gentamicin sulfate-loaded borate \n\nbioactive glass/chitosan composites. J Mater Sci Mater Med \n\n2013;24:2391\u2013 2403. doi:10.1007/s10856-013-4996-0.  \n\n\n\n47 \n\n8. Salehi S, Davis HB, Ferracane JL, Mitchell JC. Sol-gel-derived \n\nbioactive glasses demonstrate antimicrobial effects on common \n\noral bacteria. Am J Dent 2015;28:111\u2013115. \n\nhttp://www.scopus.com/ inward/record.url?eid52-s2.0-\n\n84930736821&amp;partnerID5tZOtx3y1.  \n\n9. Stoor P, Soderling E, Grenman R. Interactions between the \n\nbioactive glass S53P4 and the atrophic rhinitis-associated \n\nmicroorganism klebsiella ozaenae. J Biomed Mater Res \n\n1999;48:869\u2013874.  \n\n10. Mehrvarzfar P, Akhavan H, Rastgarian H, Akhlagi NM, \n\nSoleymanpour R, Ahmadi A. An in vitro comparative study on the \n\nantimicrobial effects of bioglass 45S5 vs. calcium hydroxide on \n\nEnterococcus faecalis. Iran Endod J 2011;6:29\u201333. \n\nhttp://www.scopus.com/inward/record.url?eid52-s2.0- \n\n80051518645&amp;partnerID5tZOtx3y1.  \n\n11. Rahaman MN, Bal BS, Huang W. Review: Emerging \n\ndevelopments in the use of bioactive glasses for treating infected \n\nprosthetic joints. Mater Sci Eng C Mater Biol Appl 2014;41:224\u2013\n\n231. doi:10.1016/j.msec.2014.04.055.  \n\n12. Davies D. Understanding biofilm resistance to antibacterial agents. \n\nNat Rev Drug Discov 2003;2:114\u2013122. doi:10.1038/nrd1008.  \n\n13. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm \n\nbacteria: Formation and comparative susceptibility to antibiotics. \n\nCan J Vet Res 2002;66:86\u201392.  \n\n14. Dongari-Bagtzoglou A. Pathogenesis of mucosal biofilm \n\ninfections: Challenges and progress. Expert Rev Anti Infect Ther \n\n2008; 6:201\u2013208. doi:10.1586/14787210.6.2.201.  \n\n15. Davey ME, O\u2019toole GA. Microbial biofilms: From ecology to \n\nmolecular genetics. Microbiol Mol Biol Rev 2000;64:847\u2013867. doi: \n\n10.1128/MMBR.64.4.847-867.2000.  \n\n16. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. \n\nOsteomyelitis and the role of biofilms in chronic infection. FEMS \n\nImmunol Med Microbiol 2008;52:13\u201322. doi:10.1111/j.1574- \n695X.2007.00357.x.  \n\n17. Hum J, Boccaccini AR. Bioactive glasses as carriers for bioactive \n\nmolecules and therapeutic drugs: A review. J Mater Sci Mater Med \n\n2012;23:2317\u20132333. doi:10.1007/s10856-012-4580-z.  \n\n\n\n48 \n\n18. Sanchez-Salcedo S, Shruti S, Salinas AJ, Malavasi G, Menabue L, \n\nVallet-Reg? M. In vitro antibacterial capacity and cytocompatibility \n\nof SiO 2-CaO-P2O5 meso-macroporous glass scaffolds enriched \n\nwith ZnO. J Mater Chem B 2014;2:4836\u20134847. \n\ndoi:10.1039/c4tb00403e.  \n\n19. Wu C, Chang J. Mesoporous bioactive glasses: Structure \n\ncharacteristics, drug/growth factor delivery and bone regeneration \n\napplication. Interface Focus 2012;2:292\u2013306. \n\ndoi:10.1098/rsfs.2011.0121.  \n\n20. Vallet-Reg? M, Ruiz-Hernandez E. Bioceramics: From bone regen- \n\neration to cancer nanomedicine. Adv Mater 2011;23:5177\u20135218. \n\ndoi:10.1002/adma.201101586.  \n\n21. Goh YF, Alshemary AZ, Akram M, Kadir MRA, Hussain R. \n\nBioactive glass: An in-vitro comparative study of doping with \n\nnanoscale copper and silver particles. Int J Appl Glas Sci \n\n2014;5:255\u2013 266. doi:10.1111/ijag.12061.  \n\n22. Bellantone M, Williams HD, Hench LL. Broad-spectrum \n\nbactericidal activity of Ag2O-doped bioactive glass. Antimicrob \n\nAgents Chemother 2002;46:1940\u20131945. \n\ndoi:10.1128/AAC.46.6.1940-1945.2002.  \n\n23. Coleman NJ. Aspects of the in vitro bioactivity and antimicrobial \n\nproperties of Ag1- and Zn21-exchanged 11 A... tobermorites. J \n\nMater Sci Med 2009;20:1347\u20131355. doi:10.1007/s10856-009- \n\n3698-0.  \n\n24. Hoppe A, Guldal NS, Boccaccini AR. A review of the biological \u20ac \n\nresponse to ionic dissolution products from bioactive glasses and \n\nglass-ceramics. Biomaterials 2011;32:2757\u20132774. doi:10.1016/ \n\nj.biomaterials.2011.01.004.  \n\n25. Lindfors NC. Bioactive glass S53P4 as a bone graft substitute in \n\nthe treatment of osteomyelitis. Bioact Glas Mater Prop Appl 2011; \n\n47:209\u2013216. doi:10.1016/B978-1-84569-768-6.50009-0.  \n\n26. Waltimo T, Brunner TJ, Vollenweider M, Stark WJ, Zehnder M. \n\nAntimicrobial effect of nanometric bioactive glass 45S5. J Dent \nRes 2007;86:754\u2013757.  \n\n27. Allan I, Newman H, Wilson M. Particulate bioglass reduces the \n\nviability of bacterial biofilms formed on its surface in an in vitro \n\nmodel. Clin Oral Implants Res 2002;13:53\u201358.  \n\n\n\n49 \n\n28. Rathke A, Staude R, Muche R, Haller B. Antibacterial activity of a \n\ntriclosan-containing resin composite matrix against three common \n\noral bacteria. J Mater Sci Mater Med 2010;21:2971\u20132977. doi: \n\n10.1007/s10856-010-4126-1.  \n\n29. Xu YT, Wu Q, Chen YM, Smales RJ, Shi SY, Wang MT. \n\nAntimicrobial effects of a bioactive glass combined with fluoride \n\nor triclosan on Streptococcus mutans biofilm. Arch Oral Biol \n\n2015;60: 1059\u20131065. doi:10.1016/j.archoralbio.2015.03.007. \n\n30. Bedoux G, Roig B, Thomas O, Dupont V, Le Bot B. Occurrence \n\nand toxicity of antimicrobial triclosan and by-products in the \n\nenvironment. Environ Sci Pollut Res Int 2012;19:1044\u20131065. doi: \n\n10.1007/s11356-011-0632-z.  \n\n31. Dann AB, Hontela A. Triclosan: Environmental exposure, toxicity \n\nand mechanisms of action. J Appl Toxicol 2011;31:285\u2013311. doi: \n\n10.1002/jat.1660.  \n\n32. Salles Branco-de-Almeida L, Mendonca Murata R, Melo Franco E, \n\nDos Santo M, De Alencar S, Koo H, Rosalen P. Effects of 7- \n\nEpiclusianone on Streptococcus mutans and caries development in \n\nrats. Planta Med 2011;77:40\u201345. doi:10.1055/s-0030-1250121.  \n\n33. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects \n\nof essential oils\u2014A review. Food Chem Toxicol 2008;46:446\u2013475. \n\ndoi:10.1016/j.fct.2007.09.106.  \n\n34. Prabhu M, Ruby Priscilla S, Kavitha K, Manivasakan P, Rajendran \n\nV, Kulandaivelu P. In vitro bioactivity and antimicrobial tuning of \n\nbioactive glass nanoparticles added with neem (Azadirachta indica) \n\nleaf powder. Biomed Res Int 2014;2014:950691\u2013950610. doi: \n\n1155/2014/950691.  \n\n35. Subapriya R, Nagini S. Medicinal properties of neem leaves: A \n\nreview. Curr Med Chem Anticancer Agents 2005;5:149\u2013146. doi: \n\n10.2174/1568011053174828. \n\n36. Bonfim RA, Chitarra VR, Gomes RT, Zacarias RD, Santos VR, \n\nVasconcelos WA. Antimicrobial activity of bioactive glass \n\nassociated to Brazilian red and green propolis. Planta Med \n2009;75: 1078. ://WOS:000268806600766.  \n\n37. Jafarzadeh Kashi T, Kasra Kermanshahi S, Erfan R, Vahid \n\nDastjerdi M, Rezaei EY, Tabatabaei FS. Evaluating the in-vitro \n\n\n\n50 \n\nantibacterial effect of Iranian propolis on oral microorganisms. Iran \n\nJ Pharm Res 2011;10:363\u2013368.  \n\n38. Liberio SA, Pereira ALA, Araujo MJAM, Dutra RP, Nascimento \n\nFRF, Monteiro-Neto V, Ribeiro MN, Goncalves AG, Guerra RNM. \n\nThe potential use of propolis as a cariostatic agent and its actions \n\non mutans group streptococci. J Ethnopharmacol 2009;125:1\u20139. \n\ndoi:10.1016/j.jep.2009.04.047.  \n\n39. Mori GG, da Rodrigues SS, Shibayama ST, Pomini M, do Amaral \n\nCOF. Biocompatibility of a calcium hydroxide-propolis \n\nexperimental paste in rat subcutaneous tissue. Braz Dent J \n\n2014;25:104\u2013108. http://www.ncbi.nlm.nih.gov/pubmed/25140713 \n\n(accessed September 18, 2016).  \n\n40. Sforcin JM. Biological properties and therapeutic applications of \n\npropolis. Phytother Res 2016;30:894\u2013905. doi:10.1002/ptr.5605.  \n\n41. Grenho L, Barros J, Ferreira C, Santos VR, Monteiro FJ, Ferraz \n\nMP, Cortes ME. In vitro antimicrobial activity and \n\nbiocompatibility of propolis containing nanohydroxyapatite. \n\nBiomed Mater 2015; 10:25004. doi:10.1088/1748-\n\n6041/10/2/025004.  \n\n42. Wu C, Chang J. Multifunctional mesoporous bioactive glasses for \n\neffective delivery of therapeutic ions and drug/growth factors. J \n\nControl Release 2014;193:282\u2013295. \n\ndoi:10.1016/j.jconrel.2014.04.026.  \n\n43. Mourino V, Boccaccini AR. Bone tissue engineering therapeutics: \n\nControlled drug delivery in three-dimensional scaffolds. JR Soc \n\nInterface 2010;7:209\u2013227. doi:10.1098/rsif.2009.0379.  \n\n44. Li Y, Liu YZ, Long T, Yu XB, Tang TT, Dai KR, Tian B, Guo YP, \n\nZhu ZA. Mesoporous bioactive glass as a drug delivery system: \n\nFabrication, bactericidal properties and biocompatibility. J Mater \n\nSci Mater Med 2013;24:1951\u20131961., doi:10.1007/s10856-013-\n\n4960-z.  \n\n45. Vallet-Regi M, Izquierdo-Barba I, Colilla M. Structure and \n\nfunctionalization of mesoporous bioceramics for bone tissue \nregeneration and local drug delivery. Philos Trans R Soc A Math \n\nPhys Eng Sci 2012;370:1400\u20131421. doi:10.1098/rsta.2011.0258.  \n\n46. Xie Z, Liu X, Jia W, Zhang C, Huang W, Wang J. Treatment of \n\nosteomyelitis and repair of bone defect by degradable bioactive \n\n\n\n51 \n\nborate glass releasing vancomycin. J Control Release 2009;139: \n\n118\u2013126. doi:10.1016/j.jconrel.2009.06.012. \n\n47. Nandi SK, Kundu B, Mukherjee P, Mandal TK, Datta S, De DK, \n\nBasu D. In vitro and in vivo release of cefuroxime axetil from \n\nbioactive glass as an implantable delivery system in experimental \n\nosteomyelitis. Ceram. Int 2009;35:3207\u20133216., doi:10.1016/j. \n\nceramint.2009.05.005.  \n\n48. Miola M, Vitale-Brovarone C, Mattu C, Verne E. Antibiotic \n\nloading on bioactive glasses and glass-ceramics: an approach to \n\nsurface modification. J Biomater Appl 2013;28:308\u2013319. \n\ndoi:10.1177/ 0885328212447665.  \n\n49. Mabrouk M, Mostafa AA, Oudadesse H, Mahmoud AA, El-Gohary \n\nMI. Effect of ciprofloxacin incorporation in PVA and PVA \n\nbioactive glass composite scaffolds. Ceram. Int 2014;40:4833\u2013\n\n4845. doi: 10.1016/j.ceramint.2013.09.033.  \n\n50. Rivadeneira J, Di Virgilio AL, Audisio MC, Boccaccini AR, \n\nGorustovich AA. Evaluation of antibacterial and cytotoxic effects \n\nof nano-sized bioactive glass/collagen composites releasing \n\ntetracycline hydrochloride. J Appl Microbiol 2014;116:1438\u20131446. \n\ndoi: 10.1111/jam.12476.  \n\n51. Domingues ZR, Cortes ME, Gomes TA, Diniz HF, Freitas CS, \n\nGomes JB, Faria AMC, Sinisterra RD. Bioactive glass as a drug \n\ndelivery system of tetracycline and tetracycline associated with \n\nbeta-cyclodextrin. Biomaterials 2004;25:327\u2013333.  \n\n52. Rivadeneira J, Di Virgilio AL, Audisio MC, Boccaccini AR, \n\nGorustovich AA. Evaluation of the antibacterial effects of \n\nvancomycin hydrochloride released from agar-gelatin-bioactive \n\nglass composites. Biomed Mater 2015;10:15011. \n\ndoi:10.1088/1748-6041/10/1/015011. \n\n53. Yao QQ, Nooeaid P, Roether JA, Dong YN, Zhang QQ, \n\nBoccaccini AR. Bioglass (R)-based scaffolds incorporating \n\npolycaprolactone and chitosan coatings for controlled vancomycin \n\ndelivery. Ceram Int 2013;39:7517\u20137522. \n\ndoi:10.1016/j.ceramint.2013.03.002.  \n\n54. Jia WT, Zhang X, Luo SH, Liu X, Huang WH, Rahaman MN, Day \n\nDE, Zhang CQ, Xie ZP, Wang JQ. Novel borate glass/chitosan \n\ncomposite as a delivery vehicle for teicoplanin in the treatment of \n\n\n\n52 \n\nchronic osteomyelitis. Acta Biomater 2010;6:812\u2013819. \n\ndoi:10.1016/ j.actbio.2009.09.011.  \n\n55. Rastegar Lari A, Bahrami Honar H, Alaghehbandan R. \n\nPseudomonas infections in Tohid Burn Center, Iran. Burns \n\n1998;24:637\u2013641. doi:10.1016/S0305-4179(98)00090-4.  \n\n56. Zhang D, Lepparanta O, Munukka E, Ylanen H, Viljanen MK, \n\nEerola E, Hupa M, Hupa L. Antibacterial effects and dissolution \n\nbehavior of six bioactive glasses. J Biomed Mater Res A 2010;93: \n\n475\u2013483. doi:10.1002/jbm.a.32564. \n\n 57. Xie ZP, Zhang CQ, Yi CQ, Qiu JJ, Wang JQ, Zhou J. Failure of \n\nparticulate bioglass to prevent experimental staphylococcal \n\ninfection of open tibial fractures. J. Antimicrob. Chemother 2008; \n\n62:1162\u20131163. doi:10.1093/jac/dkn336. \n\n 58. Coraca-Huber DC, Fille M, Hausdorfer J, Putzer D, Nogler M. \n\nEfficacy of antibacterial bioactive glass S53P4 against S. aureus \n\nbiofilms grown on titanium discs in vitro. J Orthop Res \n\n2014;32:175\u2013 177. doi:10.1002/jor.22463. \n\n 59. Bortolin M, De Vecchi E, Romano CL, Toscano M, Mattina R, \n\nDrago L. Antibiofilm agents against MDR bacterial strains: Is \n\nbioactive glass BAG-S53P4 also effective? J Antimicrob \n\nChemother 2015. doi:10.1093/jac/dkv327.  \n\n60. Drago L, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco \n\nR, Romano CL. In vitro antibiofilm activity of bioactive glass \n\nS53P4. Future Microbiol 2014;9:593\u2013601. doi:10.2217/ fmb.14.20. \n\n 61. Xavier JG, Geremias TC, Montero JFD, Vahey BR, Benfatti CAM, \n\nSouza JCM, Magini RS, Pimenta AL. Lactam inhibiting \n\nStreptococcus mutans growth on titanium. Mater Sci Eng C 2016; \n\n68:837\u2013841. doi:10.1016/j.msec.2016.07.013.  \n\n62. Liu YZ, Li Y, Yu XB, Liu LN, Zhu ZA, Guo YP. Drug delivery \n\nproperty, bactericidal property and cytocompatibility of magnetic \n\nmesoporous bioactive glass. Mater Sci Eng C Mater Biol Appl \n\n2014; 41:196\u2013205. doi:10.1016/j.msec.2014.04.037.  \n\n63. Lardner A. The effects of extracellular pH on immune function. J \n\nLeukoc Biol 2001;69:522\u2013530. http://www.jleukbio.org/content/ \n\n69/4/522.full#sec-1.  \n\n\n\n53 \n\n64. Xia W, Chang J, Lin J, Zhu J. The pH-controlled dual-drug release \n\nfrom mesoporous bioactive glass/polypeptide graft copolymer \n\nnanomicelle composites. Eur J Pharm Biopharm 2008;69:546\u2013552. \n\ndoi:10.1016/j.ejpb.2007.11.018.  \n\n65. Xia W, Chang J. Well-ordered mesoporous bioactive glasses \n\n(MBG): A promising bioactive drug delivery system. J Control \n\nRelease 2006;110:522\u2013530. doi:10.1016/j.jconrel.2005.11.002. \n\n  \n\n\n\n54 \n\n  \n\n\n\n55 \n\n3 ARTIGO 2 EM INGL\u00caS \n\nO artigo a seguir foi publicado na revista cient\u00edfica Journal of \n\nBiomedical materials research: part A. Fator de impacto: 3.263. Qualis: \n\nA1 \n\nInhibition of multi-species oral biofilm by bromide doped bioactive \n\nglass   \n\nM.E. Galarraga-Vinueza1, B. Passoni1, C. A. M. Benfatti1, J. Mesquita-\n\nGuimar\u00e3es2, B. Henriques1, R. S. Magini1, M.C. Fredel2, B. V. \n\nMeerbeek3, W. Teughels4, J. C. M. Souza1,2*   \n\n1Center for Education and Research on Dental Implants (CEPID), Post-\n\nGraduate Program in Dentistry (PPGO), Department of Dentistry \n\n(ODT), Federal University of Santa Catarina (UFSC), Florian\u00f3polis/SC, \n\n88040-900, Brazil  \n\n2Ceramic and Composite Materials Research Group (CERMAT), \n\nFederal University of Santa Catarina, Florian\u00f3polis 88040-900, Brazil  \n\n3Dept. of Oral Health Sciences, BIOMAT, University Hospitals Leuven, \n\nKatholieke Universiteit Leuven, Kapucijnenvoer 33, Leuven B-3000, \n\nBelgium  \n\n4Dept. of Oral Health Sciences, University Hospitals Leuven, \n\nKatholieke Universiteit Leuven, Kapucijnenvoer 33, Leuven B-3000, \n\nBelgium  \n\nAbstract:  \n\nBioactive glass is an attractive biomaterial that has shown excellent \n\nosteogenic and angiogenic effects for oral bone repairing procedures. \n\nHowever, anti-biofilm potential related to such biomaterial has not been \n\ncompletely validated, mainly against multi species biofilms involved in \n\nearly tissue infections. The aim of the present study was to evaluate the \n\nanti-biofilm effect of 58S bioactive glass embedding calcium bromide \n\ncompounds at different concentrations. Bioactive glass containing 0, 5, \n\nor 10wt% CaBr2 was synthesized by alkali sol-gel method and then \n\ncharacterized by physco-chemical and scanning electron microscopy \n\n(SEM). Then, samples were tested by microbiological assays using \n\noptical density, real time q-PCR, and SEM. Bioactive glass particles \n\nshowed accurate chemical composition and an angular shape with a \n\nbimodal size distribution ranging from 0.6 to 110 \u00b5m. The mean particle \n\nsize was around 29 \u00b5m. A significant anti-biofilm effect was recorded \n\n\n\n56 \n\nfor 5wt% CaBr2-doped bioactive glass against S. mitis, V. parvula, P. \n\ngingivais, S. gordoni, A. viscosus, and F. nucleatum. Such species are \n\ninvolved in the biofilm structure related to infections on hard and soft \n\ntissues in the oral cavity. The incorporation of calcium bromide into \n\nbioactive glass can be a strategy to enhance the anti-biofilm potential of \n\nbioactive glasses for bone healing and infection treatment.   \n\nKey words: Bioactive glass, anti-biofilm, bromide, sol-gel synthesis, \n\nbone infection, bone healing   \n\n3.1 INTRODUCTION  \n\nBioactive glass (BG) is a promising biomaterial developed 40 \n\nyears ago by the American scientist Larry Hench who produced the first \n\nBG of 45S5 composition with the purpose of repairing human bone \n\ndefects and derived infections [1,2]. Previous studies have widely shown \n\nthe outstanding properties on 45S5 BG, such as stimulation of \n\nosteogenic cell migration, vascularization, dissolution in bone tissue, \n\nand antibacterial effects induced by ion release [3]. In the 90s, a \n\nbioactive glass named 58S was developed via sol-gel method, in order to \n\nobtain an alternative compound with similar properties to those recorded \n\nfor 45S5. Sepulveda et al. showed that melt-derived 45S5 BG powders \n\nexhibited lower dissolution rates for hydroxyapatite formation in \n\ncomparison to those on 58S sol gel-glass powder [4]. Accordingly, \n\nhydroxyapatite is fundamental for bone healing and remodeling. Thus, \n\nthe formation of a carbonated hydroxyl-apatite (CHA) layer establishes \n\na bioactive interface between bone and BG surface, mimicking the \n\nmineral phase of bone, that also induces osteogenic cell proliferation, \n\nresulting in a desired biological match between BG particles and human \n\ntissues [1,5,6]. Nonetheless, proper bioactive response is only one of the \n\npurposes of a bioactive material. Bone infection occurs in the range of \n\n1-2.5% being an issue of orthopedic and oral surgeries [5,7,8]. In fact, \n\nbiofilms are responsible for more than 80% of human infections [9,10] \n\nwhich influence the clinical use of antibiotics after surgical procedures.  \n\nThe antibacterial effect revealed by BG has been attributed to the \n\nion release capability in increasing the pH of the surrounding medium \n\nthat can affect planktonic bacteria growth [11]. Most of the studies \nreport that the BG antibacterial effect against specific planktonic \n\nbacteria do not reflect realistic conditions of biofilm growth and \n\npathogenicity at infected areas [12\u201316]. Biofilm is a well-organized \n\nmicrobial community embedded in an extracellular polymeric matrix \n\n\n\n57 \n\ncomposed of polysaccharides, nucleic acids, proteins and water, that \n\nadheres to different surfaces  \n\nsuch as teeth, rehabilitation synthetic materials, bone, and soft \n\ntissues [17,18]. As a result of a complex well-organized structure, \n\nbacteria embedded in biofilm is 1000 times more resistant to antibiotic \n\ntherapy compared to planktonic bacteria [9,12]. Additionally, studies \n\nhave shown that biofilm formation may enhance virulence of certain \n\npathogenic bacteria like P. gingivais [19], S. mitis, F. nucleatum, A. \nviscosus, A. actinomycetemcomitans, and V. parvula [20].  In an attempt \n\nin improving BG antibacterial and anti-biofilm activity, several studies \n\nhave reported positive antibacterial properties achieved by bioactive \n\nglasses embedded with inorganic compounds containing silver, cerium, \n\nselenium, magnesium, zinc, or fluoride [14,15,21\u201324]. Bromine, a \n\nchemical element corresponding to the halogen group, has been poorly \n\nexplored in tissue engineering applications. One study reports the \n\napplication of 12-methacryloyloxydodecylpyridinium bromide (MDPB) \n\nmonomer as an antibacterial agent embedded in resinous biomaterials. \n\nThat previous study reported an effective antibacterial and anti-biofilm \n\nactivity of MDPB against S. mutans species over a period of 60 s. That \n\nwas attributed to the inhibition of an enzyme named lactate \n\ndehydrogenase activitywhich is responsible for the S. mutans \n\nmetabolism [25].  \n\nNevertheless, there are no studies reporting the incorporation of \n\nCaBr2-based compounds in BG composition to enhance its antibacterial \n\nactivity. Therefore, the aim of the present study was to produce a \n\nbioactive glass embedding calcium bromide as an innovative strategy to \n\ninhibit biofilm formation avoiding infections at bone and surrounding \n\ntissues. The null hypothesis of this study was that the presence of \n\nbromide does not affect the multi-species biofilm growth on 58S \n\nbioactive glass.    \n\n3.2 MATERIALS AND METHODS    \n\nThe methodology applied in this study to synthesize and analyze \n\n58S bioactive glass embedding CaBr2 is represented in Figure 1. First, \n\nBG (58 wt% SiO2, 33 wt% CaO, 9 wt% P2O5) powder was processed by \n\nsol-gel method following a previous study performed by the authors \n\n[26]. For that, tetraethyl orthosilicate (TEOS) (98%, Sigma Aldrich, \n\nUSA), triethyl phosphate (TEP) (99.8%, Sigma Aldrich, USA) and \n\ncalcium nitrate tetrahydrate (Ca(NO3)2\u00b74H2O) (Vetec, Brazil) were used \n\nas precursors of silicon, phosphorous and calcium oxide, respectively. \n\n\n\n58 \n\nNitric acid (HNO3, 68%, Vetec, Brazil) was used to dissolve \n\nCa(NO3)2\u00b74H2O and to adjust pH solution while ethyl alcohol (EtOH, \n\nP.A., Synth, Brazil) was used to dissolve TEOS and TEP. Molar ratio of \n\nSiO2, P2O5 and CaO was calculated, concerning the BG58S proportion. \n\nTEOS and TEP were placed in a glass recipient containing EtOH under \n\nmagnetic stirring at 25 \no\nC for 10 min. Ca(NO3)2\u00b74H2O was dissolved in \n\n2 M HNO3 and then added to water at a molar ratio TEOS:H2O of 1:4. \n\nFor bromide doped BG58S samples, calcium bromide hydrate \n\n(CaBr2.xH2O, Sigma-Aldrich, USA) was added as bromide precursor to \n\nachieve 5 or 10 wt% CaBr2. Considering the stoichiometric relation of \n\ncalcium bromide, calcium nitrate quantity was calculated to maintain the \n\nfinal amount of 33wt% CaO. The mixtures were added to the solution \n\nand stirred for 1 h. Solution was placed in a chamber at 70 \u00b0C for drying \n\nover a period of 24 h. Subsequently, the material was thermally treated \n\nat 600 \u00b0C and milled in planetarium ball mill (PM100, Retsch, \n\nGermany) at 400 rpm for 1 h, to obtain the bioactive glass powder.  BG \n\npowders were deagglomerated in a mortar agate with acetone. Then, BG \n\npowders were sieved at 106 \u00b5m and pressed at 80 MPa to obtain small \n\ndiscs of 10 mm diameter and 1 mm thickness. Thermal treatment was \n\nperformed at 1150\u00baC, by 10 \u00baC/min heating rate and 180 min of holding \n\ntime.   \n\n\n\n59 \n\n \nFigure 1. Schematic diagram showing the followed methodology to assess \n\nbiofilm inhibition \n\nPhysico-chemical and morphological analyses  \n\nAn initial chemical analysis was performed by energy dispersive \n\nX-ray spectroscopy (EDX, Swift 2000, Hitachi, Japan). The compound \n\ncomposition was obtained by rearranging the quantity of oxygen to \n\ncalculate the weight percentage of oxides using the most stable \n\nstoichiometric arrangement, resulting in a reliable tool to semi-quantify \n\nthe respective oxides. To evaluate the density of the sintered samples, \n\nthe Archimedes Principle was applied to measure the relative density of \n\nthe discs in green and after thermal treatment at 1150 \u00baC. The particle \n\nsize distribution was measured in a laser diffraction equipment \n\n(Mastersizer 2000, Malvern, UK). The powder was introduced in a wet \n\ndispersion unit with low water rotation around 1200 rpm to avoid any \n\ndeagglomeration of the sample. Before microbiological assays, the \n\nmorphologic aspects of the BG particles as well as the surfaces of the \n\ntest samples were analyzed by scanning electron microscopy (SEM), \n\n\n\n60 \n\n(TM3030, Hitachi, Japan) at 15 kV by back-scattering electron (BSE) \n\nmode. Samples were sputter-coated with gold prior to SEM analysis. \n\nThe roughness values of the disc samples were obtained regarding Rt \n\n(maximum height between peak and valley) and Ra roughness \n\nparameter that consists in the arithmetic mean value between the peak \n\nand valley height values in the effective roughness profile. The Ra \n\nroughness was recorded at five different areas on each material (n=25) \n\nusing an optical profilometer (Zygo, NewView, 7300, USA). The \n\nmeasurement length was 0.7 mm and cut off at 0.25 mm for 3 s. \n\nAfterwards, a color map and 3D model representation of the surface \n\nroughness was performed per each sample using the Mountain map \n\nSoftware (Digital Surf, France).  The X-ray diffraction (XRD) analysis \n\nwas performed on the powder and thermal treated samples to evaluate \n\nthe presence of crystalline phases in the amorphous matrix of the \n\nbioactive glass. The samples were analyzed in a diffractometer (D8 \n\nDiscover, Bruker, Germany) by using Cu K? radiation (? = 1.5406 \u00c5) \n\non theta-2 theta mode. The range of analyzed angles was at 10-70\u00ba, with \n\na step size of 0.04\u00ba and 1 s of step time. The peaks for each phase were \n\nidentified using X\u2019Pert High Score Plus Software (Panalytical, USA) \n\nwithin JCPDS patterns database.   \n\nBiofilm growth conditions  \n\nBioglass discs with different concentrations of CaBr2 (0%, 5% or \n\n10%), were tested against a multi-species biofilm, grown in a bioreactor \n\n(BIOSTAT\u00ae B, Germany) simulating the oral conditions as illustrated \n\nFigure 1. The multi-species form included 10 strains as follow: 2 early \n\ncolonizer bacterial species (Streptococcus mitis and Streptococcus \n\ngordonii), 5 pathogen bacterial species (Fusobacterium nucleatum, \nPorphyromonas gingivalis, Prevotella intermedia, Streptococcus \n\nmutans, Streptococcus sobrinus) and 3 beneficial bacterial species \n(Veillonella parvula, Actinomyces viscosus, Streptococcus salivarius). \n\n750ml of BHI II [27] 37 g/L containing brain heart infusion broth, 2.5 \n\ng/L mucin from porcine stomach type III (Sigma-Aldrich Chemie \n\nGmbH, Buchs, Switzerland), 1g/L yeast extract, 0.1 g/L L-cysteine, 2 \n\ng/L sodium bicarbonate was added to the bioreactor vessel.  Also, the \n\ncalibration of pH electrode was performed with 1/10 HCl 1/10 and the 1 \n\nmolar NaOCl before the sterilization process. Yet, one vessel of 2L was \n\nprepared with fresh BHI II, in order to be able to refresh the growth \n\nmedium twice a day, over the experiment period. After the sterilization \n\nprocess, the bioreactor was set-up with 300 rpm of stirring on anaerobic \n\n\n\n61 \n\ncondition at 37\u00b0C. Also, an anti-foam liquid was added before the \n\novernight wait.  \n\nBacterial strains were grown overnight at 37\u00b0C in BHI under \n\naerobic or anaerobic conditions, as described in the ATCC \n\nrecommendations for each strain and then incubated in the bioreactor. \n\nAfter 24 h, the bioreactor medium was supplemented with 5 mg/L \n\nhemin, 1 mg/L menadione, and the absorbance of medium was adjusted \n\nto zero. After this procedure, the absorbance of the bacterial suspension \n\nwas controlled to achieve the same optical density values prior to \n\nincubation in the bioreactor. Stable multi-species biofilm were obtained \n\nfor 72 h. After this period, BG discs were placed at the bottom of 24 \n\nwell-plates. Each well containing a BG disc was filled-up with 900 \u00b5L \n\nfresh BHI and 100 \u00b5L bioreactor culture. The negative and positive \n\ncontrol groups had pure bioglass discs. However, the negative control \n\ngroup received 900 \u00b5L fresh BHI and 100 \u00b5L bioreactor culture while \n\nthe positive control group was tested with 400 \u00b5L chlorhexidine, 500 \u00b5L \n\nfresh BHI and 100 bioreactor culture.  The 24 well plates were \n\nincubated at 37\u00b0C under anaerobic conditions over a period of 24 h \n\nbiofilm growth. Then, the supernatant was carefully removed with \n\npipets, and therefore the discs were smoothly cleaned two times with \n\n300 \u00b5L PBS to withdrawn the weakly attached biofilm. The well-\n\nattached biofilm was removed with 300 \u00b5L trypsin, into an anaerobic jar \n\nand maintained into the incubator for 15 min. The trypsin from each \n\nwell was added to Eppendorf\u2019s to be centrifuged and then the pellets \n\nwere resuspended in 500 \u00b5L PBS. On such dilution, a vitality DNA \n\nextraction was performed using 10 \u00b5L PMA and 90 \u00b5L bacterial \n\ndilution in PBS. The real time q-PCR was performed in triplicate for \n\neach strain using the ABI 7700 Sequence Detection System platform \n\n(Applied Biosystems, Foster City, CA, USA) [28]. Data was exported to \n\nan excel sheet to analyze the amount of each strain into the biofilm. For \n\nmicroscopic analyses, discs covered with biofilms were washed two \n\ntimes in PBS and fixed in glutaraldehyde 2% for 5 min. Then, discs \n\nwere washed three times in PBS, and dehydrated through a series of \n\ngraded ethanol solutions (50, 70, 80, 90, 100%). Samples covered with \n\nbiofilms were sputter-coated with gold, and analyzed by scanning \n\nelectron microscopy.   \n\n3.3 RESULTS    \n\nThe particle size distribution of BG58S particles revealed a \n\nbimodal distribution with particle size ranging from 0.6 up to 110 \u00b5m, \n\n\n\n62 \n\nas seen in Figure 2. The mean particle size was around 29 \u00b5m. The \n\nchemical composition of 58S MBG powder particles was quite similar \n\nto the expected composition (58.2 \u00b1 2 wt% SiO2, 33.01 \u00b1 1 wt% CaO, 9 \n\n\u00b1 1 wt% P2O5), as detected by EDX analyses. The EDX spectra of all \n\ncompositions are shown in Figure 3. The EDX spectra showed the \n\nhighest intensity peak for Si element. The intensity of Ca element is \n\nintermediary while the peak for P element was the lowest in the spectra. \n\nFurthermore, the bioactive glasses embedding CaBr2 revealed an \n\nincrease in the Br peak with the increase of CaBr2 in the composition.  \n\n \nFigura 2. 58S BG Bimodal particle size distribution \n\nXRD spectra for the powders and heat pressed 58S bioactive \n\nglass samples free of CaBr2 are shown in Figure 4 while XRD spectra \n\nfor samples embedding CaBr2 are shown in Figures 5 and 6. The XRD \n\nspectra of the bioactive glass powders revealed a broad diffraction band, \n\nconfirming its amorphous and glassy nature [4,31,32]. Moreover, peaks \n\nof tetracalcium phosphate (TTCP), dicalcium silicate (DCS) and \n\nbromine oxide were identified that confirmed the success of the \n\nmodified sol-gel synthesis. The increase of bromine phases was noticed \n\nwith increasing of the amount of CaBr2 in the bioactive glass \n\ncomposition. Considering the crystalline phases, XRD peaks for calcium \n\nphosphate phases, wollastonite, pseudowollastonite and quartz were \n\ndetected as tresult from the high heat treatment [32\u201336]. \n\n\n\n63 \n\nPseudowollastonite is a polymorph of wollastonite, that possesses a \n\ntransition temperature around 1250 \u00baC. However, the excess of SiO2 \n\nfavors the formation of the pseudowollastonite at lower temperatures \n\n[35,36]. In the case of the XRD spectra for BG58S 5%CaBr2, the \n\ncrystalline phases of quartz, tricalcium phosphate, wollastonite and \n\nphosphorus bromide were detected after 1150 \u00baC. The increase in the \n\ncrystallization intensity of quartz can be explained by the decomposition \n\nof dicalcium silicate, in CaO and SiO2 [35,36]. Phosphorus bromide \n\ncrystallizes from the decomposition of tetracalcium phosphate into ?-\n\ntricalcium phosphate, releasing phosphates to react with bromine oxide \n\n[35, 36]. In the case of the XRD spectra recorded for BG58S CaBr2 \n\n10wt%, calcium phosphate silicate, pseudowollastonite, wollastonite \n\nand silicon bromide phases were detected after thermal treatment at \n\n1150 \u00baC. That indicated that the silicon was not available to crystallize \n\nalone and therefore it reacted almost on totality with the bromine oxide \n\nto crystallize silicon bromide. That can be associated with the excess of \n\nCaBr2 in such chemical composition. However, the thermal treatment \n\npromoted the formation of pseudowollastonite and wollastonite [32, 35, \n\n36].  \n\n \nFigura 3. EDX spectra recorded for 58S bioactive glass free of CaBr2 and \n\nincluding 5 or 10% CaBr2 \n\n\n\n64 \n\n \nFigure 4. XRD spectra recorded for 58S bioactive glass samples free of CaBr2 \n\nprocessed at 600 or 1150 \no\nC.  \n\n \nFigure 5. XRD spectra recorded for 58S bioactive glass samples embedding 5% \n\nCaBr2 processed at 600 or 1150 \no\nC \n\n\n\n65 \n\n \nFigure 6. XRD spectra recorded for 58S bioactive glass samples embedding \n\n10% CaBr2 processed at 600 or 1150 \no\nC \n\nSEM images revealed 58S bioactive glass powder having an \n\nangular shape morphology that is typical from glass milling procedure \n\n(figure 7). BG58S samples containing CaBr2 5wt% before thermal \n\ntreatment revealed needle like crystals typical from calcium phosphate \n\nphases [29]. Such crystals disappeared and formed angular lighter \n\ncrystals like ?-Tricalcium phosphate after thermal treatment at 1150 \u00baC \n\n[30]. Surfaces of bromide-doped 58S BG discs revealed a rough \n\nmorphologic aspect associated with the content of CaBr2 as shown in \n\nfigure 7. Thus, the presence of CaBr2 seemed to affect the densification \n\nprocess of the bioactive glass. Thermal treatment performed at a higher \n\ntemperature and longer holding time should promote an increase in \n\natomic diffusion rates, leading to the formation of larger and structural \n\nordered particles.  \n\n\n\n66 \n\n \nFigure 7. SEM images of BG 58S 5wt % CaBr2 powder (A and B), 58S BG \n\ndiscs before (C, E and G) and after (D, F and H) thermal treatment \n\nincorporating 0, 5, and 10 wt % CaBr2 correspondingly  \n\nThe arithmetic average roughness (Ra) values and maximum \n\nheight between peak and valley values (Rt) recorded on 58S BG discs \n\nincreased with CaBr2 content as shown and illustrated in Figure 8.  The \n\nrelative density of the samples were determined via Archimedes method \n\nbefore and after thermal treatment. Several thermal cycles were assessed \n\nat maximum temperature ranging from 600 up to 1250 oC in order to \n\nachieve a high density for the samples. A proper maximum temperature \n\nat 1150 \u00baC of thermal treatment was selected considering final shape and \n\nhigh density for microbiological assays. The relative density of the \n\nsamples before the thermal treatment was higher than 50%. \n\n\n\n67 \n\nAdditionally, the relative density of those samples increased with the \n\nCaBr2 content. In a similar way, the sintered samples had a relative \n\ndensity of more than 74%, which increased directly with the CaBr2 \n\ncontent, achieving around 95% relative density on the highest \n\nconcentration of CaBr2 (Figure 9).   \n\n \nFigure 8. Ra, Rt roughness values, color map and 3D representation of surface \n\nroughness for 0, 5, and 10wt% CaBr2 doped 58S BG discs after thermal \n\ntreatment up to 1150\no\nC \n\n\n\n68 \n\n \nFigure 9. Relative densities of green and sintered discs of BG 58S containing or \n\nnot 5wt% or 10wt% CaBr2 \n\nBiofilm Inhibition   \n\nA significant biofilm inhibition, represented by the decrease of \n\nbacterial cell amount, was noticed when the chlorhexidine was placed in \n\ncontact with the multi-species biofilm grown on the 58SBG discs free of \n\nCaBr2. That validated the antimicrobial effect of chlorhexidine against \n\nall the early, beneficial and pathogenic species tested in this study. The \n\namount of bacteria also decreased in the presence of 58SBG discs doped \n\nwith 5% CaBr2 regarding S. mitis and S. gordonii (early colonizers), V. \nparvula and A. viscosus (beneficial species), and P. gingivalis \n\n(pathogenic species). However, no decrease of bacterial amount was \n\ndetected for multi-species biofilm grown on 58S BG discs doped with \n\n10wt% CaBr2. Results of biofilm inhibition obtained by q-PCR analyses \n\nfor early, beneficial, and pathogen bacteria are shown in Figures 10 and \n\n11.  SEM inspection of the 58S BG discs surfaces covered with multi-\n\nspecies biofilms is shown in Figure 12. Considering the morphology of \n\nthe multi-species biofilm tested in the present study, streptococcus, \n\nbacillus, and filamentous species can be detected on bioactive glass \n\nsurfaces free or containing CaBr2 after 24h of multi-species biofilm \n\ngrowth (Fig. 12). The multi-species biofilm revealed similar \n\nmorphological aspects on all the test samples inspected by SEM.   \n\n\n\n69 \n\n \nFigure 10. . Inhibition of early and beneficial oral biofilm species on 0wt% \n\nCaBr2 58S BG discs with chlorhexidine (CHX) (positive control group), 0wt% \n\nCaBr2 BG58S discs (negative control group), 5 or 10 wt% CaBr2 BG58S discs \n\n \nFigure 11. Inhibition of pathogen oral biofilm species on 0wt% CaBr2 BG58S \n\ndiscs with chlorhexidine (CHX) (positive control group), 0wt% CaBr2 BG58S \n\ndiscs (negative control group), and 5, 10 wt% CaBr2 BG58S discs \n\n\n\n70 \n\n \nFigure 12. SEM images of multi-species biofilm adherence on BG58S discs \n\nwith 0wt%CaBr2 (A,B), 5wt% CaBr2(C,D) and 10 wt% CaBr2(E,F)  \n\n3.4 DISCUSSION   \n\nThe present study incorporated calcium bromide as a potential \n\nanti-biofilm compound into BG composition, which for the first time \n\nhas been explored in tissue engineering applications. Accordingly, the \n\nresults of this study has supported the hypothesis that BG modified with \n\ncalcium bromide is able to inhibit different bacteria in multi-species oral \n\nbiofilm revealed by real time q-PCR analysis. This study demonstrated \n\nan appropriate chemical and bimodal size distribution of BG particles \n\nand that BG samples embedding 5wt% CaBr2 had an anti-biofilm effect \n\nagainst early, beneficial and pathogen oral biofilm species.  \nBG embedding 5wt% CaBr2 had a notorious anti-biofilm effect \n\nagainst species such as S. mitis, S. gordonii, A. viscosus, V. parvula, and, \n\nP. gingivalis. Conversely, no biofilm inhibition was distinguished for \nBG samples embedding 10wt% CaBr2, probably due to the higher \n\nroughness values revealed by the discs surfaces corresponding to this \n\n\n\n71 \n\nexperimental group. A high roughness seemed to affect negatively the \n\nanti-biofilm potential. Previous studies have reported that surfaces with \n\nhigher roughness have more compatibility with biofilm adherence \n\nbecause bacteria is sheltered against shear forces. Additionally, biofilm \n\nadhesion area increases with the increment of roughness, which allows \n\nbiofilm accumulation [39\u201341]. SEM analysis of biofilm adherence in the \n\ndisk samples of this study did not show differences between the control \n\nand experimental groups; nevertheless, this is a qualitative analysis \n\nwhich only reveals the presence of certain species and is not as precise \n\nas q-PCR analysis.  \n\nFurthermore, tissue engineering has been challenged to improve \n\nBG chemical composition considering biocompatibility and antibacterial \n\neffects. In the present study, the crystalline phases analysis revealed the \n\npresence of bioactive phases for bone healing such as tetracalcium \n\nphosphate and dicalcium silicate [32,34,37]. Regarding BG58S 5wt% \n\nCaBr2 processed at 1150 \u00baC, the XRD spectra (Fig 5) also revealed the \n\npresence of phosphorus bromide. Phosphorus tribromide is a compound \n\nused in pharmacology as an active compound of anti-inflammatory, \n\nanalgesic and antipyretic reactions. Also, BG58S CaBr2 5wt% presented \n\nthe crystal microstructures typical from calcium phosphates phases, \n\nwhich is an indication of a high bioactivity.   \n\nSeveral previous studies have shown suitable antibacterial \n\nproperties achieved by bioactive glasses doped with diverse oxides [10-\n\n12]. However, possible toxic effects caused by metallic ions and \n\nparticles embedded into BG are still a controversial concern for clinical \n\napplications. Most studies have tested antibacterial properties of \n\nmodified bioactive glasses against planktonic bacteria solely [7,15,42]. \n\nGoh et al. reported that BG samples modified with 5 and 10 mol% \n\ncerium oxide demonstrated a significant antibacterial activity against E. \ncoli, evaluated by the quantitative viable count method [14]. \n\nAdditionally, El-Kady et al. established in their study that all BG \n\nnanoparticles doped with 1, 3, 5, and 10wt% Ag2O had antibacterial \n\neffect against S. aureus and E. coli cultures evaluated by the disk \n\ndiffusion method. That study attributed the high effective antibacterial \n\neffect to the presence of silver ions [13]. In contrast, Fooladi et al. stated \n\nthat silver is not an essential component for inhibiting bacterial growth \n\n[24]. That study incorporated MgO into BG nanopowders and its \n\nantibacterial effect was assessed against E. coli, P. aureginosa, and S. \n\naureus. The BG nanopowders at a greater concentration than 15.62 \n\nmg/mL showed efficient inhibitory effects on the three bacterial strains. \n\nAs well, selenium nanoparticles have also being added to BG as an \n\n\n\n72 \n\nantibacterial agent. Stevanovic et al. showed in their study that BG 45S5 \n\nwith selenium nanoparticles had a significant antibacterial activity \n\nagainst S. aureus and S. epidermis cultures, and inhibited B. subtilis and \nK. pnuemoniae growth [23]. Fluorine has also being added to BG \n\nparticles as an antimicrobial agent. Xu et al. showed in their study that \n\nBG particles mixed with sodium fluoride (NaF) had a significant S. \nmutans  biofilm inhibition effect after 24 hours of exposure. That study \n\ntested the anti-biofilm effect against one oral bacteria (monospecie \n\nbiofilm); nevertheless, currently there are not enough studies testing \n\nmodified bioactive glass against multi-species oral biofilms. Fluorides \n\nare known to inhibit bacterial enzymes like enolase and catalase. Also, \n\ncompounds with fluorine may disrupt bacterial cell membranes and \n\ncytoplasm pH, and interfere glycolysis of cariogenic bacteria [15]. \n\nBromine has many similar characteristics to fluorine although bromine \n\nhas not being incorporated into BG composition as an antibiofilm agent \n\nin previous studies. Considering a lack of findings on the effect of Br \n\nbased compounds, this study pursued the objective of testing bromide \n\ndoped BG as a new repairing biomaterial to inhibit multispecies oral \n\nbiofilm.   \n\nThe results of the present study are promising since bromide had \n\nan anti-biofilm effect against early, beneficial, and pathogen oral \n\nspecies. Nevertheless, future studies evaluating anti-biofilm properties \n\nof CaBr2 doped BG samples should take in consideration that samples \n\ncharacteristics, such as surface roughness are of extreme importance \n\nregarding biofilm adherence. One limitation of the present study was \n\nthat samples of the tested groups had different surface roughness values; \n\nconsequently, biofilm inhibition was evaluated under different \n\ncircumstances in each study group.  \n\nIn addition, forthcoming studies should evaluate the \n\nbiocompatibility and the hydroxyapatite formation capability of \n\ninnovative bromide doped BG to be tested in future in vivo studies. \n\nRegarding the mechanism in which bromine acts as anti-biofilm agent, \n\nnew studies should analyze how bromine ions are able to affect biofilm \n\nformation and additionally include clinical strains isolated from patients \n\nreporting infection in implanted sites to mimic conditions that are more \n\nrealistic to clinical complications.    \n\n3.5 CONCLUSION \n\nWithin the limitations of this study, the main outcomes of this \n\nwork are drawn as follow:  \n\n\n\n73 \n\n\u2022 The chemical composition of the CaBr2-doped bioactive \nwas monitored and therefore the powder particles showed \n\nan angular shape and bimodal size distribution. That plays \n\nan important role on the clinical application in bone defects; \n\n\u2022 Considering microbiological assessment, bioactive glass \ndoped with 5wt% CaBr2 had a considerable anti-biofilm \n\neffect against oral bacteria involved in a multi-species \n\nbiofilm. Such findings are more representative concerning \n\nthe aggregation pathways among different species when \n\ncompared to mono-species methods related in literature. In \n\nfact, biomaterials embedding potential antibiofilm \n\ncompounds must be tested against multi-species biofilms as \n\nreported in the present study  \n\n\u2022 CaBr2-doped bioactive glass can be considered an \nadvantageous anti-biofilm biomaterial for clinical \n\napplications and treatment of oral infections at implanted \n\nsurgical sites. Notwithstanding, other bromide contents and \n\ncompositions should be assessed by physicochemical and \n\nbiological tests in further studies to clarify the anti-biofilm \n\nbehavior of such enhanced bioactive glasses.     \n\n3.6 REFERENCES   \n\n[1] J.R. Jones, Review of bioactive glass: From Hench to hybrids, \n\nActa Biomaterialia. 9 (2013) 4457\u20134486. \n\ndoi:10.1016/j.actbio.2012.08.023.  \n\n[2] L.L. Hench, J.R. Jones, Bioactive Glasses: Frontiers and \n\nChallenges., Frontiers in Bioengineering and Biotechnology. 3 \n\n(2015) 194. doi:10.3389/fbioe.2015.00194.  \n\n[3] A. Hoppe, N.S. G\u00fcldal, A.R. Boccaccini, A review of the \n\nbiological response to ionic dissolution products from bioactive \n\nglasses and glass-ceramics, Biomaterials. 32 (2011) 2757\u20132774. \n\ndoi:10.1016/j.biomaterials.2011.01.004.  \n\n[4] P. Sepulveda, J.R. Jones, L.L. Hench, In vitro dissolution of melt-\n\nderived 45S5 and sol-gel derived 58S bioactive glasses., Journal \n\nof Biomedical Materials Research. 61 (2002) 301\u201311. \n\ndoi:10.1002/jbm.10207.  \n\n[5] H. Wang, S. Zhao, X. Cui, Y. Pan, W. Huang, S. Ye, S. Luo, \n\nM.N. Rahaman, C. Zhang, D. Wang, Evaluation of three-\n\n\n\n74 \n\ndimensional silver-doped borate bioactive glass scaffolds for \n\nbone repair: Biodegradability, biocompatibility, and antibacterial \n\nactivity, Journal of Materials Research. 30 (2015) 2722\u20132735. \n\ndoi:10.1557/jmr.2015.243.  \n\n[6] M.N. Rahaman, B.S. Bal, W. Huang, Review: emerging \n\ndevelopments in the use of bioactive glasses for treating infected \n\nprosthetic joints., Materials Science &amp; Engineering. C, Materials \n\nfor Biological Applications. 41 (2014) 224\u201331. \n\ndoi:10.1016/j.msec.2014.04.055.  \n\n[7] A.M. El-Kady, A.F. Ali, R.A. Rizk, M.M. Ahmed, Synthesis, \n\ncharacterization and microbiological response of silver doped \n\nbioactive glass nanoparticles, Ceramics International. 38 (2012) \n\n177\u2013188. doi:10.1016/j.ceramint.2011.05.158.  \n\n[8] Z.-P. Xie, C.-Q. Zhang, C.-Q. Yi, J.-J. Qiu, J.-Q. Wang, J. Zhou, \n\nIn vivo study effect of particulate Bioglass\u00ae in the prevention of \n\ninfection in open fracture fixation, Journal of Biomedical \n\nMaterials Research - Part B Applied Biomaterials. 90 (2009) \n\n195\u2013201. doi:10.1002/jbm.b.31273.  \n\n[9] D. Davies, Understanding biofilm resistance to antibacterial \n\nagents., Nature Reviews. Drug Discovery. 2 (2003) 114\u201322. \n\ndoi:10.1038/nrd1008.  \n\n[10] A. Dongari-Bagtzoglou, Pathogenesis of mucosal biofilm \n\ninfections: challenges and progress., Expert Review of Anti-\n\nInfective Therapy. 6 (2008) 201\u20138. \n\ndoi:10.1586/14787210.6.2.201.  \n\n[11] M. Gubler, T.J. Brunner, M. Zehnder, T. Waltimo, B. Sener, W.J. \n\nStark, Do bioactive glasses convey a disinfecting mechanism \n\nbeyond a mere increase in pH?, International Endodontic Journal. \n\n41 (2008) 670\u2013678. doi:10.1111/j.13652591.2008.01413.x.  \n\n[12] M.E. Olson, H. Ceri, D.W. Morck, A.G. Buret, R.R. Read, \n\nBiofilm bacteria: Formation and comparative susceptibility to \n\nantibiotics, Canadian Journal of Veterinary Research. 66 (2002) \n\n86\u201392.  \n\n[13] A.M. El-Kady, A.F. Ali, R.A. Rizk, M.M. Ahmed, Synthesis, \n\ncharacterization and microbiological response of silver doped \n\nbioactive glass nanoparticles, Ceramics International. 38 (2012) \n\n177\u2013188. doi:10.1016/j.ceramint.2011.05.158.  \n\n\n\n75 \n\n[14] Y.F. Goh, A.Z. Alshemary, M. Akram, M.R. Abdul Kadir, R. \n\nHussain, In-vitro characterization of antibacterial bioactive glass \n\ncontaining ceria, Ceramics International. 40 (2014) 729\u2013737. \n\ndoi:10.1016/j.ceramint.2013.06.062.  \n\n[15] Y.-T. Xu, Q. Wu, Y.-M. Chen, R.J. Smales, S.-Y. Shi, M.-T. \n\nWang, Antimicrobial effects of a bioactive glass combined with \n\nfluoride or triclosan on Streptococcus mutans biofilm., Archives \n\nof Oral Biology. 60 (2015) 1059\u20131065. \n\ndoi:10.1016/j.archoralbio.2015.03.007.  \n\n[16] M.E. Galarraga-Vinueza, J. Mesquita-Guimar\u00e3es, R.S. Magini, \n\nJ.C.M. Souza, M.C. Fredel, A.R. Boccaccini, Anti-biofilm \n\nproperties of bioactive glasses embedding organic active \n\ncompounds, Journal of Biomedical Materials Research Part A. \n\n(2016) 672\u2013679. doi:10.1002/jbm.a.35934.  \n\n[17] J.C.M. Souza, R.R.C. Mota, M.B. Sordi, B. Bernardo, Biofilm \n\nFormation on Different Materials Used in Oral Rehabilitation, 27 \n\n(2016) 141\u2013147. doi:10.1590/0103-6440201600625.  \n\n[18] J.G. Xavier, T.C. Geremias, J.F.D. Montero, B.R. Vahey, C.A.M. \n\nBenfatti, J.C.M. Souza, R.S. Magini, A.L. Pimenta, Lactam \n\ninhibiting Streptococcus mutans growth on titanium, Materials \n\nScience &amp; Engineering C. 68 (2016) 837\u2013 841. \n\ndoi:10.1016/j.msec.2016.07.013.  \n\n[19] S. Clais, G. Boulet, M. Kerstens, T. Horemans, W. Teughels, M. \n\nQuirynen, E. Lanckacker, I. De Meester, A.-M. Lambeir, P. \n\nDelputte, L. Maes, P. Cos, Importance of biofilm formation and \n\ndipeptidyl peptidase IV for the pathogenicity of clinical \n\nPorphyromonas gingivalis isolates., Pathogens and Disease. 70 \n\n(2014) 408\u201313. doi:10.1111/2049-632X.12156.  \n\n[20] F. Carrouel, S. Viennot, J. Santamaria, P. Veber, D. Bourgeois, \n\nQuantitative Molecular Detection of 19 Major Pathogens in the \n\nInterdental Biofilm of Periodontally Healthy Young Adults., \n\nFrontiers in Microbiology. 7 (2016) 840. \n\ndoi:10.3389/fmicb.2016.00840.  \n\n[21] O. Lysenko, O. Dubok, A. Borysenko, O. Shinkaruk, The \n\nbiological properties of the silver- and copper-doped ceramic \n\nbiomaterial, Journal of Nanoparticle Research. 17 (2015). \n\ndoi:10.1007/s11051-015-2971-z.  \n\n\n\n76 \n\n[22] V. Anand, K.J. Singh, K. Kaur, Evaluation of zinc and \n\nmagnesium doped 45S5 mesoporous bioactive glass system for \n\nthe growth of hydroxyl apatite layer, Journal of Non-Crystalline \n\nSolids. 406 (2014) 88\u201394. doi:10.1016/j.jnoncrysol.2014.09.050.  \n\n[23] M. Stevanovi?, N. Filipovi?, J. Djurdjevi?, M. Luki?, M. \n\nMilenkovi?, A. Boccaccini, 45S5Bioglass\u00ae-based scaffolds \n\ncoated with selenium nanoparticles or with poly(lactide-co-\n\nglycolide)/selenium particles: Processing, evaluation and \n\nantibacterial activity, Colloids and Surfaces B: Biointerfaces. 132 \n\n(2015) 208\u2013 215. doi:10.1016/j.colsurfb.2015.05.024.  \n\n[24] A.A. Imani Fooladi, H.M. Hosseini, F. Hafezi, F. Hosseinnejad, \n\nM.R. Nourani, Sol-gel-derived bioactive glass containing SiO2-\n\nMgO-CaO-P 2O5 as an antibacterial scaffold, Journal of \n\nBiomedical Materials Research - Part A. 101 A (2013) 1582\u2013\n\n1587. doi:10.1002/jbm.a.34464.  \n\n[25] N. Izutani, S. Imazato, K. Nakajo, N. Takahashi, Y. Takahashi, S. \n\nEbisu, R.R.B. Russell, Effects of the antibacterial monomer \n\n12methacryloyloxydodecylpyridinium bromide (MDPB) on \n\nbacterial viability and metabolism., European Journal of Oral \n\nSciences. 119 (2011) 175\u201381. doi:10.1111/j.1600-\n\n0722.2011.00817.x.  \n\n[26] J. Mesquita-Guimaraes, M.A. Leite, J.C.M. Souza, B. Henriques, \n\nF.S. Silva, D. Hotza, A.R. Boccaccini, M.C. Fredel, Processing \n\nand strengthening of 58S bioactive glass-infiltrated titania \n\nscaffolds, Journal of Biomedical Materials Research - Part A. \n\n(2016) 590\u2013600. doi:10.1002/jbm.a.35937.  \n\n[27] G. Alvarez, M. Gonz\u00e1lez, S. Isabal, V. Blanc, R. Le\u00f3n, Method to \n\nquantify live and dead cells in multi-species oral biofilm by real-\n\ntime PCR with propidium monoazide., AMB Express. 3 (2013) 1. \n\ndoi:10.1186/2191-0855-3-1.  \n\n[28] Qiagen, PCR Protocols &amp;amp; Applications - QIAGEN, (n.d.).  \n\n[29] L.R. Rodrigues, M.S. De Laranjeira, M.H. Fernandes, F.J. \n\nMonteiro, C.A. De Carvalho Zavaglia, HA/TCP scaffolds \n\nobtained by sucrose crystal leaching method: Preliminary in vitro \n\nevaluation, Materials Research. 17 (2014) 811\u2013816. \n\ndoi:10.1590/S1516-14392014005000082.  \n\n\n\n77 \n\n[30] Z. Sheikh, S. Najeeb, Z. Khurshid, V. Verma, H. Rashid, M. \n\nGlogauer, Biodegradable materials for bone repair and tissue \n\nengineering applications, Materials. 8 (2015) 5744\u20135794. \n\ndoi:10.3390/ma8095273.  \n\n[31] S. Joughehdoust, S. Manafi, Synthesis and in vitro investigation \n\nof sol-gel derived bioglass-58S nanopowders, Materials Science-\n\nPoland. 30 (2012) 45\u201352. doi:10.2478/s13536-012-0007-2.  \n\n[32] M. Taghian Dehaghani, M. Ahmadian, M. Fathi, Synthesis, \n\nCharacterization, and Bioactivity Evaluation of Amorphous and \n\nCrystallized 58S Bioglass Nanopowders, International Journal of \n\nApplied Ceramic Technology. 874 (2014) 867\u2013874. \n\ndoi:10.1111/ijac.12293. This article is protected by copyright. All \n\nrights reserved. \n\n[33] M. a. Encinas-romero, S. Aguayo-Salinas, S.J. Castillo, F.F. \n\nCastill\u00f3n-Barraza, V.M. Casta\u00f1o, Synthesis and characterization \n\nof hydroxyapatite-wollastonite composite powders by sol-gel \n\nprocessin, International Journal of Applied Ceramic Technology. \n\n5 (2008) 401\u2013411. doi:10.1111/j.1744-7402.2008.02212.x.  \n\n[34] M.A. Encinas-romero, J. Peralta-haley, J.L. Valenzuela-garc\u00eda, \n\nSynthesis and Structural Characterization of Produced by an \n\nAlternative Sol-Gel Route, 2013 (2013) 327\u2013333.  \n\n[35] O.M. Goudouri, X. Chatzistavrou, E. Kontonasaki, N. Kantiranis, \n\nL. Papadopoulou, K. Chrissafis, K.M. Paraskevopoulos, Study of \n\nthe Bioactive Behavior of Thermally Treated Modified 58S \n\nBioactive Glass, Key Engineering Materials. 396\u2013398 (2009) \n\n131\u2013134. doi:10.4028/www.scientific.net/KEM.396398.131.  \n\n[36] M.M. Obeid, Crystallization of Synthetic Wollastonite Prepared \n\nfrom Local Raw Materials, International Journal of Materials and \n\nChemistry. 4 (2014) 79\u201387. doi:10.5923/j.ijmc.20140404.01.  \n\n[37] W. Lu, W. Duan, Y. Guo, C. Ning, Mechanical properties and in \n\nvitro bioactivity of Ca5(PO4)2SiO4 bioceramic., Journal of \n\nBiomaterials Applications. 26 (2012) 637\u201350. \n\ndoi:10.1177/0885328210383599.  \n\n[38] P. Gao, H. Zhang, Y. Liu, B. Fan, X. Li, X. Xiao, P. Lan, M. Li, \n\nL. Geng, D. Liu, Y. Yuan, Q. Lian, J. Lu, Z. Guo, Z. Wang, Beta-\n\ntricalcium phosphate granules improve osteogenesis in vitro and \n\nestablish innovative osteo-regenerators for bone tissue \n\n\n\n78 \n\nengineering in vivo., Scientific Reports. 6 (2016) 23367. \n\ndoi:10.1038/srep23367.  \n\n[39] W. Teughels, N. Van Assche, I. Sliepen, M. Quirynen, Effect of \n\nmaterial characteristics and/or surface topography on biofilm \n\ndevelopment., Clinical Oral Implants Research. 17 Suppl 2 \n\n(2006) 68\u201381. doi:10.1111/j.16000501.2006.01353.x.  \n\n[40] M. Quirynen, C.M. Bollen, The influence of surface roughness \n\nand surface-free energy on supra- and subgingival plaque \n\nformation in man. A review of the literature., Journal of Clinical \n\nPeriodontology. 22 (1995) 1\u201314. This article is protected by \n\ncopyright. All rights reserved. 22   \n\n[41] C.M. Bollen, P. Lambrechts, M. Quirynen, Comparison of \n\nsurface roughness of oral hard materials to the threshold surface \n\nroughness for bacterial plaque retention: a review of the \n\nliterature., Dental Materials?: Official Publication of the Academy \n\nof Dental Materials. 13 (1997) 258\u201369.  \n\n[42] Y.-F. Goh, A.Z. Alshemary, M. Akram, M.R. Abdul Kadir, R. \n\nHussain, Bioactive Glass: An In-Vitro Comparative Study of \n\nDoping with Nanoscale Copper and Silver Particles, International \n\nJournal of Applied Glass Science. 5 (2014) 255\u2013266. \n\ndoi:10.1111/ijag.12061. This article is protected by copyright. All \n\nrights reserved. \n\n  \n\n\n\n79 \n\n4 ARTIGO 3 EM INGL\u00caS \n\nO artigo a seguir ser\u00e1 submetido na revista cient\u00edfica Journal of \n\nBiomedical materials research: part A. Fator de impacto: 3.263. Qualis: \n\nA1 \n\nMesoporous bioactive glass embedding propolis and cranberry \n\nantibiofilm compounds  \n\nM.E. Galarraga-Vinueza\n1\n, J. Mesquita-Guimar\u00e3es\n\n2\n, R. S. Magini\n\n1\n, J. C. \n\nM. Souza\n1,2\n\n, M. C. Fredel\n2\n, A. R. Boccaccini\n\n3* \n\n1\nCenter for Education and Research on Dental Implants (CEPID), Post-\n\nGraduation Program in Dentistry (PPGO), Department of Dentistry \n\n(ODT), Federal University of Santa Catarina(UFSC), Florianopolis/SC, \n\n88040-900, Brazil \n2\nCeramic and Composite Materials Research Group (CERMAT), \n\nFederal University of Santa Catarina, Florianopolis 88040-900, Brazil \n3\nInstitute of Biomaterials, Department of Materials Science and \n\nEngineering, University of Erlangen-Nuremberg, 91058 Erlangen, \n\nGermany \n\nCorresponding author: A.R. Boccaccini; e-mail: \n\naldo.boccaccini@ww.uni-erlangen.de \n\nAbstract:  \n\nBioactive glasses are attractive materials for bone repairing procedures \n\ndue to their desirable osteoconductive, angiogenic, osteogenic, and \n\nantibacterial properties.  In addition, the antibacterial properties of \n\nbioactive glass can be enhanced depending on the glass porous structure \n\nand chemical composition. The aim of the present study was to evaluate \n\nthe chemical reactivity of 58S mesoporous bioactive glass free or \n\nembedding propolis and cranberry antibiofilm compounds at different \n\nconcentrations. Mesoporous 58S bioactive glass (MBG) was synthesized \n\nby alkali sol-gel method with the addition of the triblock pluronic \n\ncopolymer P123 as surfactant. Samples were characterized by physco-\n\nchemical properties measurement, N2 adsorption/desorption analysis, \n\nand field emission scanning electron microscopy (FESEM) \nobservations. MBG powders were immersed into 5 and 10 \u00b5g/ml \n\npropolis or cranberry solutions for 24 h. The chemical reactivity of the \n\nspecimens was evaluated by FESEM, EDX, FTIR and Ca/P analysis \n\nafter being immersed in simulated body fluid (SBF) solution for 8, 24 \n\n\n\n80 \n\nand 72 h. MBGs had the expected chemical composition with a particle \n\nsize distribution ranging from 1.44 up to 955 \u00b5m, and a mean particle \n\nsize of 154 \u00b5m. MBG particles exhibited a pore volume of 0.8 cc/g, a \n\npore radius of about 2 nm and a surface area at 350.2 m\n2\n/g, according to \n\nBJH and BET analyses. A hydroxyl-carbonate apatite (HCAp) layer was \n\nformed on all samples after SBF immersion for 72 h. Pure MBG showed \n\nthe highest chemical reactivity after 72 h and therefore the resulting \n\napatite layer revealed a Ca/P ratio of 1.8, corresponding to non-\n\nstoichiometric biological apatite. MGB embedding propolis and \n\ncranberry can be considered for future microbiological analysis since \n\ntheir modified composition did not interfere with the ability of MBG to \n\ndevelop a HCAp layer on its surface, which is an  essential property for \n\nbone regeneration applications. \n\nKey words: mesoporous bioactive glass, anti-biofilm, sol-gel synthesis, \n\nbioactivity, propolis, cranberry PACS, bone healing \n\n4.1 INTRODUCTION  \n\nMore than 45 years ago, Hench et al. developed the first bioactive \n\nglass (BG) of composition: (46.1 mol.% SiO2, 24.4 mol.% Na2O, 26.9 \n\nmol.% CaO and 2.6 mol.% P2O5); with the purpose of generating a \n\nbiomaterial that could bond to bone fulfilling the requirements of \n\northopedic surgeries of the time[1]. After many years of bioactive glass \n\nintensive research, BGs have been demonstrated to be outstanding \n\nmaterials due to their desirable characteristics such as high bioactivity, \n\nosteogenic stimulation, angiogenic effect, ability to bond to soft tissues, \n\nhigh biocompatibility and antibacterial activity induced by its ion \n\nrelease capability [2\u201310]. It is well established that highly bioactive \n\nsynthetic glasses bond to bone through the formation of a hydroxyl-\n\ncarbonate apatite (HCAp) layer which mimics the mineral phase of \n\nbone; thus, resulting in a biological match between BGs and bone \n\ntissues [3,10]. Certainly, bioactivity accomplished through a high \n\nchemical reactivity in contact with human tissues  is the most acclaimed \n\nproperty of bioactive glasses; nevertheless, new tissue engineering \n\nrequirements have emerged besides this property to fulfill the necessities \n\nof surgical and regenerative procedures which include also applications \nin soft tissue repair [6,7,9].  \n\nSeveral new BG compositions have been developed over the \n\nyears to improve bioactivity and mechanical properties[6,10]. Recent \n\nadvances have considered BG structures characterized by nano-porous \n\norganized arrangements, known as mesoporous bioactive glass (MBG), \n\n\n\n81 \n\nwhich are developed by the sol-gel method [11\u201314]. MBGs exhibit large \n\nsurface area with organized nano-porous channels which can induce a \n\nhigher HCAp formation and allow the incorporation of bioactive \n\nmolecules such as bone morphogenetic proteins (BMP) and vascular \n\nendothelial growth factor (VEGF) to induce osteogenesis and \n\nangiogenesis [12,14]. Furthermore, MBGs can act as drug delivery \n\nsystems by the incorporation and release of antibiotics, antibacterial and \n\nantibiofilm compounds in their nano porous structure [11,12,14,15].  \n\nStudies have reported that orthopedic and craniofacial surgeries \n\nhave a considerable risk of postoperative bone infection and that bone \n\nimplant associated infections are major complications of bone repairing \n\nprocedures [4,5,16\u201318]. Systemic antibiotic therapy is the most common \n\ntreatment of bone-associated infections. However, such therapy can \n\ncause a bacterial resistance of pathogenic species considering the \n\nformation of biofilms [14]. It should be highlighted that biofilms consist \n\nof a well-organized microbial community embedded in an extracellular \n\npolymeric matrix composed of polysaccharides, nucleic acids, proteins \n\nand water  being  the main cause of implanted bone infections \n\n[17,19,20]. Bacteria organized in a multispecies biofilm is 1000 times \n\nmore resistant to antibiotics when compared to planktonic bacteria [19]. \n\nThus, BGs have been considered as favorable biomaterials to locally \n\ncounteract grafted or implanted site infections due to their antibacterial \n\neffect accomplished by raising the pH of the medium, which affects \n\nplanktonic bacterial growth [8]. Only few studies have reported the \n\neffect of BG on multispecies  biofilm as found in the oral cavity [4,21]. \n\nSeveral antibiotics such as gentamicin, teicoplanin, tetracycline, \n\nvancomycin, and cefuroxime axetil [22\u201326] have being loaded into \n\nMBGs leading to favorable antibacterial effects. However, the \n\nantibiofilm effect of MBG loaded with antibiotics has not been \n\ncompletely validated in these studies. Hence, it is of clinical relevance to \n\nincorporate antibiofilm rather than antibacterial compounds into MBG \n\nfor an effective infection treatment [27].  \n\nPrevious studies have reported the incorporation of natural \n\nderived antibiofilm compounds into BG and MBG [28\u201330]. Surface \n\nfunctionalization of BGs has been explored for the incorporation of \n\nnatural biomolecules such as polyphenols, which have potential \n\nantibacterial benefits[30]. Additionally, a herbal derived substance \n\ncalled propolis, which is a resinous natural substance collected by bees, \n\nhas being described to have several health promoting properties like \n\nfibroblast stimulation, antioxidant activity, antifungal and antiviral \n\nactivity, antibiofilm inhibition and counteraction  of bacteria virulent \n\n\n\n82 \n\nfactors [29,31]. Propolis has shown non-cytotoxic effects, but it has not \n\nbeen deeply explored in tissue engineering applications [32,33]. Only \n\none study [29] has incorporated red and green propolis collected from \n\ndifferent regions into BG, showing a satisfactory growth inhibition of  S. \n\naureus, E. faecalis, S. mutans, P. intermedia, F. nucleatum, P. \n\ngingivalis, and, A. actinomycetemcomitans. Moreover, other natural \ncompounds, such as A-type proanthocyanidins (PACS) derived from the \n\ncranberry fruit (Vaccinium macrocarpon) have also demonstrated a \npotential antibiofilm effect[34]. Initially, cranberry PACS were widely \n\nstudied to prevent and treat urinary tract infections since they prevent \n\nbacterial adhesion to uroepithelial cells [34,35]. Additionally, Kim et al. \n\nreported that PACS are capable of inhibiting bacterial adhesion on the \n\nexopolysaccharide (EPS) matrix which provides biofilm mechanical \n\nstability for microbial proliferation [36]. Other studies have also shown \n\nthat cranberry PACS neutralize S. mutans virulence factors and increase \n\nthe medium pH leading to changes of biochemical and ecological factors \n\nfor cariogenic biofilm development [37,38]. On the other hand, even \n\nthough several studies have reported the antibiofilm potential of \n\ncranberry PACS[34\u201338], that compound has not been incorporated into \n\nbiomaterials to treat bone-derived infections and for bone regeneration.  \n\nAccordingly, this study pursuits to integrate natural derived \n\nantibiofilm substances in bioactive glasses. In particular, a novel \n\nmesoporous bioactive glass incorporating propolis and cranberry \n\nantibiofilm compounds was developed. The hypothesis behind this work \n\nis that the incorporation of propolis and cranberry compounds will not \n\naffect the inherent bioactivity of 58S mesoporous bioactive glass, \n\ndeveloping thus a material , which is both effective against biofilm \n\nformation and suitable to bond to bone without addition of antibiotic \n\ndrugs.  \n\n4.2 MATERIALS AND METHODS    \n\n4.2.1 MBG sol-gel synthesis  \n\nMBG (58 wt% SiO2, 33 wt% CaO, 9 wt% P2O5) (58S \n\ncomposition) powder was processed via a sol-gel technique. First, 4 g of  \n\npluronic triblock copolymer P123 (EO20PO70EO20, 5800, Sigma \nAldrich, USA) surfactant was dissolved in 50 mL ethanol by using a \n\nstirring bar at 40 \n?\nC for 1 h. Afterwards, tetraethyl orthosilicate (TEOS) \n\n(98%, Sigma Aldrich, USA), triethyl phosphate (TEP) (99.8%, Sigma \n\nAldrich, USA) and calcium nitrate tetrahydrate (Ca(NO3)2\u00b74H2O) \n\n\n\n83 \n\n(Vetec, Brazil) were added to the solution as precursors of silicon, \n\nphosphorous and calcium oxide. The solution was stirred at  40\n?\nC for 12 \n\nh. Nitric acid (HNO3, 68%, Vetec, Brazil) was used to dissolve \n\nCa(NO3)2\u00b74H2O and to adjust the pH of the solution while ethyl alcohol \n\n(EtOH, P.A., Synth, Brazil) was used to dissolve P123, TEOS and TEP. \n\nThe molar ratios of SiO2, P2O5 and CaO were calculated, concerning the \n\n58S MBG proportion. TEOS and TEP were placed in a glass recipient \n\ncontaining EtOH under magnetic stirring at 25 \no\nC for 10 min. \n\nCa(NO3)2\u00b74H2O was dissolved in 2 M HNO3 and then added to water at \n\na molar ratio TEOS:H2O of 1:4. Then, the solution was placed for \n\ndrying in a chamber at 70 \u00b0C over a period of 24 h. Subsequently, the \n\ndried gel was thermally treated at 600 \u00b0C for 6 h at a heating rate of \n\n1\u00baC/min to remove the organic agents and the surfactant template. The \n\nmethodology used in this study is schematically shown in Figure 1. \n\n \n\n \nFigure 1. Schematic diagram showing the methodology applied in this study to \n\nprepare MBG incorporating propolis and cranberry PACS.  \n\n4.2.2 Physicochemical characterization  \n\nThe particle size distribution was measured in a laser diffraction \n\nequipment (Mastersizer 2000, Malvern, UK). The powder was \n\nintroduced in a wet dispersion unit with low water rotation (~1200 rpm) \nto avoid significant agglomeration of the particles. \n\n\n\n84 \n\nChemical analysis of the samples was performed using energy \n\ndispersive X-ray spectroscopy (EDX, Swift 2000, Hitachi, Japan). The \n\ncompound composition was obtained by rearranging the quantity of \n\noxygen to calculate the weight percentage of oxides using the most \n\nstable stoichiometric arrangement, resulting in a reliable tool to semi-\n\nquantify the respective oxides. The functional groups of the powder \n\nsamples were identified by Fourier transform infrared spectroscopy \n\n(FTIR, Cary 600 Series, Agilent technologies, USA), performed by KBr \n\npellet technique. Pellets were prepared by mixing 1 mg of each sample \n\npowder and 300 mg KBr at infrared grade under vacuum. The infrared \n\nspectra were recorded in a wavenumber of 400-4000 cm\n-1\n\n in \n\ntransmission mode with 32 scans and resolution of 4 cm\n-1\n\n. \n\nMBG textural analysis was performed by N2 adsorption and \n\ndesorption isotherms measured by a porosity analyzer (AUTOSORB-1-\n\n1 C, Quantochrome) at -203.85\n?\nC. Pore size distribution and volume \n\nwere determined from the isotherm adsorption branch applying the \n\nBarrett-Joyner-Halenda (BJH) method while the surface area was \n\nestablished by the Brunauer-Emmett-Teller (BET) method. The \n\nmorphologic aspects of the MBG particles were analyzed by field \n\nemission gun scanning electron microscopy (FESEM) (Zeiss Leica, \n\nGermany) at an acceleration potential of 5 kV.  \n\n4.2.2 In vitro loading of propolis and cranberry compounds  \n\nGreen propolis dry extracts from Baccharis dracunculifolia sp. \n\n(Natucentro\u00ae, Minas Gerais, Brazil) and Cranberry PAC dry extracts \n\nfrom Vaccinium macrapon sp. (Naturex-DBS\u00ae , Massachusetts, USA) \n\nwere diluted in a 50% (v/v) hydro-alcoholic solution (EtOH, P.A., \n\nSynth, Brazil) under magnetic stirring at room temperature for 5 h to \n\nprepare solutions of 5 and 10 ?g/mL as described in a previous study \n\n[31].  Then, 0.5 g of MBG powders were immersed into 50 mL of the \n\ncorresponding solutions with different concentrations and stirred at 37\u00b0C \n\nfor 24 h. MBG powders were also added into a hydro-alcoholic solution \n\nfree of natural derived compounds to prepare the control group. After \n\nimmersion, the solutions containing MBG powders were centrifuged \n\nand dried in a vacuum oven at 40 \u00b0C for 3 h.  \n\n4.2.3 In vitro apatite-forming assays  \n\nSimulated body fluid (SBF) solution was prepared following \n\nKokubo\u00b4s method [39]. The chemical composition of the SBF solution \n\nis shown in Table 1. MBG powders (75 mg) were immersed into 50 mL \n\n\n\n85 \n\nof SBF solution in sterilized PS flasks. The flasks were placed in an \n\nincubator (IKA, Germany) at 37\u00b0C and stirred at 90 rpm for 8, 24 or 72 \n\nh. At the end of each period, the samples were centrifuged, removed by \n\nfiltration, washed with deionized water and dried in a vacuum oven at \n\n37\u00b0C for 24 h [40]. Each sample was run in triplicate. Afterwards, the \n\nHCAp-forming ability of all samples was evaluated by SEM, EDX, and \n\nFTIR analysis.  \n\nTable 1.  Chemical composition of the SBF stock solution [40] \n\nORDER  REAGENT  AMOUNT (g/l) \n\n1 NaCl 8.035 \n\n2 NaHCO  0.355 \n\n3 KCl 0.225 \n\n4 K2HPO4 3H2O 0.231 \n\n5 MgCl2 6H2O 0.311 \n\n6 HCl 1M 38 mL \n\n7 CaCl2 2H2O 0.386 \n\n8 Na2SO4 0.072 \n\n9 Tris  6.118 \n\n4.3 RESULTS    \n\n4.3.1 Characterization of MBG particles \n\nMBG particle size ranged from 1.44 up to 955 \u00b5m, revealing a \n\nGaussian-like distribution, as seen in Figure 2A. The mean particle size \n\nwas around 154 \u00b5m. The actual chemical composition of 58S MBG \n\nparticles was close to the expected composition (58.22 \u00b1 2 wt% SiO2, \n\n33.091 \u00b1 3 wt% CaO, 8.6 \u00b1 1 wt% P2O5) as shown in Figure 2B. EDX \n\nspectra showed the highest intensity peak for the Si element, followed \n\nby Ca element and P element (Figure 2B).  \n\nThe FTIR analysis showed BG characteristic peaks of Si-O-Si \n\nwhere the main absorption bands were at 1080, 810 cm\n-1\n\n, attributed to \n\nthe Si-O-Si asymmetric stretching, and at 460 cm\n-1\n\n attributed to Si-O-Si \n\nbending, as demonstrated in Figure 3.  \n\n\n\n86 \n\n \n\nFigure 2. (A) MBG 58S particle size distribution and (B) EDX results for 58S \n\nMBG. \n\nThe textural analysis regarding N2 adsorption-desorption \n\nisotherms, BJH pore size distribution and volume are shown in Figure 4. \n\n58S MBG N2 adsorption-desorption isotherms (Figure 4A) corresponded \n\nto a type IV curve of the International Union of Pure and Applied \n\nChemistry (IUPAC) classification which is typical of mesoporous \n\nmaterials showing a H1 type hysteresis loop [41]. The initial part of this \n\ncurve can be associated to monolayer-multilayer adsorption. Also, a \n\nlimiting uptake in a range of high P/Po was noted[42]. In addition, the \n\nsharp steps in adsorption and desorption branches at 0.7-0.8 and 0.6-0.7 \n\nP/Po regions respectively, are associated to capillary condensation at \nmesopores. The BHJ method revealed that MBG particles had a mean \n\nnarrow pore radius at 2 nm, as shown in Figure 4B, and a porosity \n\nvolume of about 0.83 cc/g. The MBG specific surface area was 350.2 \n\nm\n2\n/g according to BET analysis.  \n\n\n\n87 \n\n \nFigure 3. FTIR spectrum obtained for 58S mesoporous bioactive glasses \n\n(relevant peaks are indicated). \n\n \nFigure 4. (A) N2 adsorption (red)-desorption (blue) isotherms and (B) BJH pore \n\nradius distribution curves for 58S mesoporous bioactive glass particles.  \n\nFESEM micrographs revealed a fairly regular and uniform \n\nappearance of MBG particles, as seen in Figure 5A. At higher \n\n\n\n88 \n\nmagnifications, MBG particles showed an angular shape and non-\n\nsmooth porous structure, having pores below 10 nm in diameter, as \n\nobserved in Figure 5B and 5C. Also, sphere-like structures below 100 \n\nnm are noticed in Figure 5C, probably indicating crystallized ?-\n\nTricalcium phosphate which may have formed after thermal treatment of \n\nthe samples as described elsewhere [4].  \n\n \nFigure 5. (A-C) FESEM images of 58S MBG 58S particles at different \n\nmagnifications. In (C) nano-pores (white squares) are revealed at 80,000X \n\nmagnification.   \n\n4.3.2 In vitro apatite-forming assays  \n\nFESEM images revealed that the surface of all samples was \n\nrelatively smooth and did not exhibit any HCAp formation after \n\nimmersion in SBF for 8 h (Fig. 6). After 24 h, all MBG samples \n\nchanged their surface morphology having a more granular-like \n\nappeareance. For 72 h of immersion, all samples showed spherical-like \n\nstructures which indicates the formation of apatite crystals. The control \n\n58S MBG  particles showed an apatite layer formed over their surface \n\nupon 24 h of immersion in SBF, as seen in Figure 6A whereas almost all \n\nMBG particles were covered with an HCAp layer. MBG particle \n\nsurfaces were covered with a thick HCAp layer revealing spherical, \n\nneedle, polygonal, and cauliflower-shaped crystals.  \n\nIn the case of MBG particles embedding 5 \u00b5g/ml cranberry \n\nPACS, an increase of roughness seemed to take place after 24 h \n\nimmersion in SBF. Also, the surface was covered with sphere-shaped \n\napatite crystals after 72 h of immersion in SBF, as seen at higher \n\nmagnification (Figure 6B, white squares). In the case of MBG \n\nembedding 10 \u00b5g/ml cranberry PACs, the sample surface was still \n\nsmooth after 24h of immersion when compared to the control group. \n\nOnly some round plain structures could be detected on MBG embedding \n\n10 \u00b5g/ml cranberry (Figure 6C). On FESEM micrographs, MBG \n\n\n\n89 \n\nparticles embedding 10 \u00b5g/ml cranberry showed the lowest HCAp \n\nformation after 24 h among all samples. After 72 h of immersion, the \n\nsurface of MBG embedding 10 \u00b5g/ml cranberry was not smooth \n\nanymore due to the presence of numerous small rounded apatite \n\nstructures (Fig. 6C).  \n\nMBG particles embedding both propolis concentrations are \n\nshown in Figures 6D and 6E. Both samples showed the development of \n\nan HCAp layer after 24 h of immersion in SBF that was more noticeable \n\nwhen compared to the other experimental group samples. After 72 h, a \n\ncauliflower shaped apatite layer could be clearly detected for both \n\nMBG/propolis containing samples, as seen in Figure 6D and 6E at the \n\nhighest magnification micrographs (white squares).  \n\nEDS analyses were performed in triplicate for all samples to \n\ndetermine the Ca/P atomic ratio, as shown in Table 2. The EDS spectra \n\nanalysis showed non-significant changes in MBG composition for all \n\nsamples after immersion in SBF for 8 h (Fig. 7). After 24 h, EDS \n\nshowed an increase in Ca and P wt% while Si wt% decreased in all \n\nsamples. Generally, MBG samples showed a notorious Si wt% loss and \n\na higher wt% P after immersion in SBF for 72 h. EDS analysis on MBG \n\nembedding 5\u00b5g/ml propolis revealed Si as the main element followed by \n\nCa and P after immersion in SBF for 8 h (Fig. 7A). However, a decrease \n\nin Si content and increase in P and Ca concentrations are noticed after \n\n24 immersion in SBF (Fig. 7B). This result can be linked to the presence \n\nof a thick HCAp layer as shown in the SEM micrograph. Finally, after \n\n72h, figure 7C shows an EDS spectrum exhibiting a lower Si wt% and \n\nhigher P wt% corresponding to the formation of HCAp, which is \n\nexpected after immersion in SBF for 72 h (Fig. 7C), as seen by SEM \n\nmicrographs. The Ca/P ratios shown in Table 2 indicate that the \n\nunloaded MBG sample reached a Ca/P ratio of 1.8 after immersion in \n\nSBF for 72h, which is in accordance to non-stoichiometric HCAp ratio \n\n[43]. The samples embedding propolis in both concentrations revealed \n\nCa/P ratios close to the HCAp reference value after 72 h of immersion \n\nin SBF. MBG sample embedding 5 \u00b5g/ml of cranberry PACs showed a \n\nratio of 2.03 although MBG embedding the higher cranberry PACs \n\nconcentration had a Ca/P ratio of 2.85.  \n\n\n\n90 \n\n \nFigure 6.FESEM micrographs at 10,000X recorded on 58S MBG particles after \n\nimmersion in SBF for 8, 24 and 72 h. MBG (A) Pure and containing (B) 5 \n\n\u00b5g/ml cranberry PACS, (C) 10 \u00b5g/ml cranberry PACs, (D) 5\u00b5g/ml propolis \n\nand (E) 10 \u00b5g/ml propolis. Red squares exhibit corresponding micrographs at \n50,000X.  \n\n\n\n91 \n\n \nFigure 7. SEM images (1,000X) and EDX analysis recorded on MBG \n\ncontaining 5 \u00b5g/ml propolis particles immersed in SBF solution for (A) 8 h, (B) \n24 h and (C) 72 h.  \n\nTable 2. Ca/P elemental concentration ratio of samples before and after SBF \n\nimmersion for 0, 8, 24 and 72 h  \n\n \n\nThe samples of the present study after 8 and 24 hours of SBF \n\nimmersion did not show significant compositional changes in the FTIR \n\nspectra. The FTIR spectra of MBG with 5 or 10 \u00b5g/ml of propolis and \n\ncranberry PACS were similar after 72h of immersion. Figure 8 exhibits \n\nthe spectra for MBG incorporating 5 \u00b5g/ml for both compounds.  The \n\nFTIR spectra of all samples presented the characteristic peaks attributed \n\nto HCAp layer formation as a doublet at around ~600 cm\n-1 \n\ncorresponding to the bending mode of crystalline phosphate P-O and P-\n\nO stretching mode at ~1050 cm\n-1\n\n, where the resonance was more intense \n\nespecially for the spectrum of  pure MBG. On the other hand the \n\nspectrum of MBG before SBF immersion indicates the absence of the \n\nmentioned double peak. Additionally, resonances attributed to the \n\nphosphate group were present in the spectra of pure MBG, MBG/ \n\ncranberry PACS and MBG/propolis. A narrowing band at around 820 \n\ncm\n-1\n\n corresponds to the bending mode of C-O and at around 1400cm\n-1\n\n a \n\nTime   \n\nSBF \n\n(h) \n\nMBG \n\n58s \n\n \n\nMBG/prop \n\n5 \u00b5g/ml \n\nMBG/prop \n\n10 \u00b5g/ml \n\nMBG/PACS \n\n5 \u00b5g/ml \n\nMBG/PACS \n\n10 \u00b5g/ml \n\n0  7.16 \u00b1 1 6.67 \u00b1 1 6.56 \u00b1 1,5 8.1 \u00b1 1 7.03 \u00b1 1 \n\n8  4.89 \u00b1 2 5.7 \u00b1 2 6.02 \u00b1 1 7.3 \u00b1 1,5 7.01 \u00b1 2.5 \n\n24  2.01 \u00b1 1 4.08 \u00b1 1.5 5.08 \u00b1 1 6.04 \u00b1 1 6.07 \u00b1 1.5 \n\n72  1.81\u00b11.5 1.9 \u00b1 1.6 2.01 \u00b1 1.5 2.03 \u00b1 2 2.85 \u00b1 1 \n\n\n\n92 \n\npeak corresponding to the C-O stretching mode can also be observed in \n\nthe pure MBG spectrum. In addition, at ~1680 cm\n-1\n\n the resonance \n\ncorresponding to C-O in CO3\n2-\n\n can also be observed indicating the \n\nformation of a carbonated HAp due the presence of CO2 in SBF. \n\n \nFigure 8.  FTIR spectra obtained for 58S mesoporous bioactive glass samples \n\n(free MBG, MBG-5 \u00b5g/ml propolis and MBG-5 \u00b5g/ml cranberry PACS) \nbefore and after 72 h of SBF immersion. (Red circle identifies the double peak \n\ncharacteristic of HCAp formation) \n\n4.4 DISCUSSION  \n\nThe present work synthesized mesoporous bioactive glass \n\nincorporating propolis and cranberry compounds in order to enhance the \n\nbioactive properties and anti-biofilm potential of MBG for bone healing \n\nand infection treatment procedures. The results of the present study \n\nsupported the hypothesis that natural derived compounds incorporated \ninto MBG did not interfere with the inherent bioactivity of this \n\nbiomaterial. This study demonstrated an appropriate physical, chemical, \n\nand particle size distribution of MBG samples. Moreover, the addition \n\nof the surfactant P123 to the sol gel synthesis did not change the \n\n\n\n93 \n\ncharacteristic chemical composition of 58S BG, as confirmed by EDX \n\nand FTIR analysis. \n\nFurthermore, the textural analysis showed that the synthesized \n\nMBG particles had a meso-porous structure of pore size of 4nm, with a \n\nhigh volume and specific surface area making it capable to incorporate \n\nin its structure therapeutic agents as a drug delivery system. The \n\nmesoporous structure of the synthesized MBG could be determined by \n\nits IV N2 adsorption and desorption isotherm curve with a H1-type \n\nhysteresis loop at high relative pressure according to the IUPAC \n\nclassification [11,42]. The present study is supported by previous \n\ninvestigations showing the same type of hysteresis loop in the N2 \n\nisotherms for mesoporous materials [12,14,44,45], however in this study \n\nthe organization and arrangement of the meso-pores were not confirmed \n\n(e.g. by TEM). In addition, previous studies developing MBGs have \n\nshown higher surface area, pore volume, and pore diameter that should \n\nenhance the MBG capability to incorporate therapeutic agents in their \n\nnano-structure and favor a higher HCAp formation to bond with bone \n\nreceptor tissues [46]. A high surface area increases the amount of Si-O \n\nbonds to interact with loaded therapeutic agent molecules and a high \n\npore diameter and volume enables a larger space for drug load and \n\nsustained delivery. Furthermore, diverse biomolecules such as BMPs \n\nand VEGF can covalently bond to MBG surfaces to stimulate specific \n\ntarget cells for osteogenesis and angiogenesis  [46,47]. Even though the \n\npresent study showed appropriate meso-pore characteristics, other \n\nstructure directing agents could be applied such as F127, F108, P85, \n\nCTAB, and P123+CTAB, reported in other studies [12,48], to increase \n\nthe surface area and volume of MBG improving in this way the \n\nmentioned therapeutic, bioactive and osteogenic characteristics [14].   \n\nThe simulated body fluid test is widely accepted to evaluate the \n\nbioactivity of a material in terms of its ability since it mimics the \n\nprocess in which a biomaterial is able to bond to bone tissues through \n\nthe formation of a bone like apatite layer [39,40]. As follows, the \n\nmechanism of MBG apatite formation involves a series of steps. First, \n\nan exchange between calcium and hydrogen ions occurs. Consequently, \n\nsilanol forms over the surface of the biomaterial and polymerizes \n\nproducing an amorphous silica gel.  Afterwards, calcium and phosphate \n\nions migrate to the newly formed silica gel and start forming an HCAp \n\nlayer, which finally crystallizes forming needle and cauliflower-shaped \n\nstructures which promote the attachment of bone cells [49]. In this \n\nstudy, MBG free or incorporating propolis and cranberry compounds did \n\nnot exhibit apatite formation after 8 h in SBF solution; however, all the \n\n\n\n94 \n\nsamples were able to induce a significant HCAp layer after 72 h in SBF. \n\nAdditionally, pure MBG samples revealed through chemical and \n\nmicroscopic analysis the greatest HCAp formation after 24 and 72 h, \n\nwhere their surface was completely covered by needle like and \n\ncauliflower-shaped crystals typical of the process of HCAp \n\ncrystallization [43,50,51]. Nevertheless, MBGs immersed in propolis \n\nand cranberry solutions were also able to develop an HCAp layer after \n\n72 h. Only the highest concentration of cranberry PACS solution \n\nseemed to interfere with the HCAp forming capability of MBG \n\nparticles. The highest concentration (10 \u00b5g/ml) of cranberry PACS \n\nnegatively affected the bioactivity of the samples which can be observed \n\nin FESEM micrographs and Ca/P values comparable to 1.8 which \n\ncorresponds to non-stoichiometric hydroxyapatite [43]. Furthermore, \n\npure MBG, 5-10 \u00b5g/ml propolis and 5\u00b5g/ml cranberry MBGs had a \n\nCa/P value close to 1.8 demonstrating the presence of HCAp. In \n\naddition, EDX analysis exhibited after 24 and 72 h a notorious increase \n\nof calcium and phosphate wt% in all samples indicating the formation of \n\na calcium phosphate layer over MBG particles by the reaction of Ca\n2+\n\n \n\nand PO4\n3-\n\n ions from SBF solution. These results are relevant for  the \n\nintended applications in bone regeneration, since released Ca, Si and P \n\nions from MBG particles can improve cell proliferation through HCAp \n\nlayer formation, as reported in previous studies [49,52]. Finally, FTIR \n\nanalysis did not show any significant change in the chemical \n\ncomposition of the samples after 8 h of SBF immersion. MBG \n\nincorporating propolis and cranberry compounds at both concentrations \n\nexhibited similar FTIR spectra after 72 h in SBF. As shown in figure 8, \n\nFTIR spectra for all samples after 72 h showed characteristic peaks \n\nattributed to HCAp layer formation as other studies report [53,54]. \n\nResonance bands attributed to P-O and C-O were observed in all \n\nsamples especially in pure MBG particles. This chemical analysis \n\nsupports FESEM observations, which indicated that samples were able \n\nto develop an HCAp layer after 72 h of SBF immersion. This \n\nobservation has clinical relevance since this HCAp layer on MBG \n\nsurface layers facilitates bone contact few days after the surgical \n\nprocedure. \n\nBGs have been modified over the years with the incorporation of \n\ndiverse antibacterial and antibiofilm agents to counteract bone infection. \n\nVarious studies have reported the incorporation of metal oxides, \n\nantibiotics and other organic agents into bioactive glasses[11\u201316]; \n\nhowever, there is no consensus until present days of which antibiofilm \n\nagent is the most effective for bone infection treatment [8,41,55\u201357]. \n\n\n\n95 \n\nIndeed, the BG S53P4 is being successfully commercialized to \n\ncounteract osteomyelitis conditions [58\u201360]. Taking in consideration \n\nthat some metal ions have toxic effects in the human body [61], the \n\npresent study investigated for the first time embedding in MBG two \n\nnatural derived antibiofilm components consumed by humans which \n\nhave no toxic effects [33,35]. Propolis and cranberry antibiofilm \n\ncompounds have complex and rich phytochemical compositions of \n\ndiverse elements such as flavonoids, steroids, amino acids, phenolic and \n\naromatic compounds, which vary in composition and quantity \n\ndepending on their growing conditions [62,63]. For this reason, the \n\npresent study used propolis and cranberry compounds that already had \n\nchromatographic analysis and were previously standardized for \n\ncommercial distribution. A difficulty of this study was to develop a \n\nprotocol to incorporate propolis and cranberry compounds into bioactive \n\nglass mesoporous structures since there are no previous related studies \n\nthat have followed an established and replicable methodology. \n\nConsequently, this study followed standard methods to develop an \n\n?accurate? procedure to embed propolis and cranberry compounds into \n\nMBG through the immersion technique. In addition, the main objective \n\nof the present study was to evaluate the bioactivity of the modified \n\nMBGs since this is an essential and desired characteristic of this \n\nbiomaterial. Further studies are required to understand the mechanisms \n\nin which these natural agents bond to MBG surfaces, how its delivery \n\ntakes place and if their antibiofilm potential is effective to treat bone \n\ninfections. Certainly, nature\u00b4s incomparable properties via antibiofilm \n\ncompounds can be explored in novel biomaterial combinations, in this \n\ncase with MBG, to develop a superior biomaterial system able to \n\naccomplish tissue-engineering goals with simultaneous anti-infection \n\noutcome. \n\n4.5 CONCLUSION  \n\nThe main conclusions of this study and perspectives for further \n\nreserach are the following: \n\n \n\n? MBG (58S) exhibited favorable physical properties, \nespecially their mesoporous structure, that can act as a drug \n\ndelivery system targeting specific areas where therapeutic \n\nagents are required, representing an alternative to systemic \n\nantibiotic therapy. \n\n\n\n96 \n\n? All samples were able to induce an HCAp layer formation \non MBG particles after 72 h of SBF immersion, which is \n\nimportant for clinical applications since such HCAp layer on \n\nMBG enables bone contact only few days after the grafting \n\nprocedure.  \n\n? The incorporation of propolis and cranberry PACS \ncompounds reported as antibiofilm agents did not inhibit the \n\nHCAp formation ability of MBG, thus imparting their \n\nantibiofilm properties for bone repair and infection \n\ntreatment. \n\n? Further studies are needed to assess the effects provided by \nthe antibiofilm agent confined and delivered through MBG \n\nnano-pores and to develop release triggers such as pH, \n\ntemperature, and light, which could make the delivery \n\nsystem more effective and sustained. \n\nAcknowledgements \n\nThe authors acknowledge the financial support provided by the \n\ngovernment research funding agency CNPq (Brazil) and by the Institute \n\nfor Biomaterials at the Department of Materials Science and \n\nEngineering, University of Erlangen-Nuremberg. \n\n4.6 REFERENCES  \n\n[1] L.L. Hench, R.J. Splinter, W.C. Allen, T.K. Greenlee, Bonding \n\nmechanisms at the interface of ceramic prosthetic materials, J. \n\nBiomed. Mater. Res. 5 (1971) 117\u2013141. \n\ndoi:10.1002/jbm.820050611. \n\n[2] A. Hoppe, N.S. G\u00fcldal, A.R. Boccaccini, A review of the \n\nbiological response to ionic dissolution products from bioactive \n\nglasses and glass-ceramics, Biomaterials. 32 (2011) 2757\u20132774. \n\ndoi:10.1016/j.biomaterials.2011.01.004. \n\n[3] L.L. Hench, Opening paper 2015- Some comments on Bioglass: \n\nFour Eras of Discovery and Development, Biomed. Glas. 1 \n\n(2015) 1\u201311. doi:10.1515/bglass-2015-0001. \n\n[4] M.E. Galarraga-Vinueza, B. Passoni, C.A.M. Benfatti, J. \n\nMesquita-Guimar\u00e3es, B. Henriques, R.S. Magini, et al., Inhibition \n\nof multi-species oral biofilm by bromide doped bioactive glass, J. \n\nBiomed. Mater. Res. Part A. (2017). doi:10.1002/jbm.a.36056. \n\n\n\n97 \n\n[5] L. Drago, E. De Vecchi, M. Bortolin, M. Toscano, R. Mattina, \n\nC.L. Roman\u00f2, Antimicrobial activity and resistance selection of \n\ndifferent bioglass S53P4 formulations against multidrug resistant \n\nstrains, 10 (2015) 1293\u20131299. \n\n[6] M.N. Rahaman, D.E. Day, B. Sonny Bal, Q. Fu, S.B. Jung, L.F. \n\nBonewald, et al., Bioactive glass in tissue engineering, Acta \n\nBiomater. 7 (2011) 2355\u20132373. doi:10.1016/j.actbio.2011.03.016. \n\n[7] A.A. Gorustovich, J.A. Roether, A.R. Boccaccini, Effect of \n\nbioactive glasses on angiogenesis: a review of in vitro and in vivo \n\nevidences., Tissue Eng. Part B. Rev. 16 (2010) 199\u2013207. \n\ndoi:10.1089/ten.TEB.2009.0416. \n\n[8] M.E. Galarraga-Vinueza, J. Mesquita-Guimar\u00e3es, R.S. Magini, \n\nJ.C.M. Souza, M.C. Fredel, A.R. Boccaccini, Anti-biofilm \n\nproperties of bioactive glasses embedding organic active \n\ncompounds, J. Biomed. Mater. Res. Part A. 105 (2017) 672\u2013679. \n\ndoi:10.1002/jbm.a.35934. \n\n[9] V. Miguez-Pacheco, L.L. Hench, A.R. Boccaccini, Bioactive \n\nglasses beyond bone and teeth: Emerging applications in contact \n\nwith soft tissues, Acta Biomater. 13 (2015) 1\u201315. \n\ndoi:10.1016/j.actbio.2014.11.004. \n\n[10] J.R. Jones, Review of bioactive glass: from Hench to hybrids., \n\nActa Biomater. 9 (2013) 4457\u201386. \n\ndoi:10.1016/j.actbio.2012.08.023. \n\n[11] Y. Li, Y.Z. Liu, T. Long, X. Bin Yu, T.T. Tang, K.R. Dai, et al., \n\nMesoporous bioactive glass as a drug delivery system: \n\nFabrication, bactericidal properties and biocompatibility, J. \n\nMater. Sci. Mater. Med. 24 (2013) 1951\u20131961. \n\ndoi:10.1007/s10856-013-4960-z. \n\n[12] C. Wu, J. Chang, Mesoporous bioactive glasses: structure \n\ncharacteristics, drug/growth factor delivery and bone regeneration \n\napplication, Interface Focus. 2 (2012) 292\u2013306. \n\ndoi:10.1098/rsfs.2011.0121. \n\n[13] M. Vallet-Reg\u00ed, E. Ruiz-Hern\u00e1ndez, Bioceramics: From Bone \n\nRegeneration to Cancer Nanomedicine, Adv. Mater. 23 (2011) \n\n5177\u20135218. doi:10.1002/adma.201101586. \n\n[14] C. Wu, J. Chang, Multifunctional mesoporous bioactive glasses \n\n\n\n98 \n\nfor effective delivery of therapeutic ions and drug/growth \n\nfactors., J. Control. Release. 193 (2014) 282\u2013295. \n\ndoi:10.1016/j.jconrel.2014.04.026. \n\n[15] J. Hum, A.R. Boccaccini, Bioactive glasses as carriers for \n\nbioactive molecules and therapeutic drugs: a review., J. Mater. \n\nSci. Mater. Med. 23 (2012) 2317\u201333. doi:10.1007/s10856-012-\n\n4580-z. \n\n[16] V. Mourino, A.R. Boccaccini, Bone tissue engineering \n\ntherapeutics: controlled drug delivery in three-dimensional \n\nscaffolds, J. R. Soc. Interface. 7 (2010) 209\u2013227. \n\ndoi:10.1098/rsif.2009.0379. \n\n[17] J. Geurts, J.J. Chris Arts, G.H.I.M. Walenkamp, Bone graft \n\nsubstitutes in active or suspected infection. Contra-indicated or \n\nnot?, Injury. 42 Suppl 2 (2011) S82-6. \n\ndoi:10.1016/j.injury.2011.06.189. \n\n[18] W. Teughels, N. Van Assche, I. Sliepen, M. Quirynen, Effect of \n\nmaterial characteristics and/or surface topography on biofilm \n\ndevelopment., Clin. Oral Implants Res. 17 Suppl 2 (2006) 68\u201381. \n\ndoi:10.1111/j.1600-0501.2006.01353.x. \n\n[19] D. Davies, Understanding biofilm resistance to antibacterial \n\nagents., Nat. Rev. Drug Discov. 2 (2003) 114\u201322. \n\ndoi:10.1038/nrd1008. \n\n[20] A. Mombelli, N. M\u00fcller, N. Cionca, The epidemiology of peri-\n\nimplantitis, Clin. Oral Implants Res. 23 (2012) 67\u201376. \n\ndoi:10.1111/j.1600-0501.2012.02541.x. \n\n[21] Y.-T. Xu, Q. Wu, Y.-M. Chen, R.J. Smales, S.-Y. Shi, M.-T. \n\nWang, Antimicrobial effects of a bioactive glass combined with \n\nfluoride or triclosan on Streptococcus mutans biofilm., Arch. Oral \n\nBiol. 60 (2015) 1059\u20131065. \n\ndoi:10.1016/j.archoralbio.2015.03.007. \n\n[22] Y.L. Zhou, J. Chang, Study on Gentamicin Loading and Release \n\nfrom Mesoporous Bioactive Glasses (MBGs) with Different \nShapes, Chemical Composition and Surface Property, J. \n\nBiomater. Tissue Eng. 2 (2012) 177\u2013183. \n\ndoi:10.1166/jbt.2012.1038. \n\n[23] X. Zhang, W.-T. Jia, Y.-F. Gu, C.-Q. Zhang, W.-H. Huang, D.-P. \n\n\n\n99 \n\nWang, Borate bioglass based drug delivery of teicoplanin for \n\ntreating osteomyelitis, Wuji Cailiao Xuebao/Journal Inorg. Mater. \n\n25 (2010) 293\u2013298. doi:10.3724/SP.J.1077.2010.00293. \n\n[24] S.K. Nandi, B. Kundu, P. Mukherjee, T.K. Mandal, S. Datta, \n\nD.K. De, et al., In vitro and in vivo release of cefuroxime axetil \n\nfrom bioactive glass as an implantable delivery system in \n\nexperimental osteomyelitis, Ceram. Int. 35 (2009) 3207\u20133216. \n\ndoi:10.1016/j.ceramint.2009.05.005. \n\n[25] Z. Xie, X. Liu, W. Jia, C. Zhang, W. Huang, [Vancomycin-\n\nloaded bioactive borate glass for treatment of chronic \n\nosteomyelitis in rabbits]., Zhongguo Xiu Fu Chong Jian Wai Ke \n\nZa Zhi. 25 (2011) 830\u2013836. \n\nhttp://www.scopus.com/inward/record.url?eid=2-s2.0-\n\n84859894925&amp;partnerID=tZOtx3y1. \n\n[26] E. Vanea, S. Cavalu, F. B?nic?, Z. Benyey, G. G\u00f6ller, V. Simon, \n\nAdsorption and release studies of tetracycline from a bioactive \n\nglass, Stud. Univ. Babes-Bolyai Chem. (2011) 239\u2013246. \n\nhttp://www.scopus.com/inward/record.url?eid=2-s2.0-\n\n84855268676&amp;partnerID=40&amp;md5=e47ba7dc6fbe80733da45074\n\n2a2c5bdc. \n\n[27] M.E. Olson, H. Ceri, D.W. Morck, A.G. Buret, R.R. Read, \n\nBiofilm bacteria: Formation and comparative susceptibility to \n\nantibiotics, Can. J. Vet. Res. 66 (2002) 86\u201392. \n\n[28] M. Prabhu, S. Ruby Priscilla, K. Kavitha, P. Manivasakan, V. \n\nRajendran, P. Kulandaivelu, In Vitro Bioactivity and \n\nAntimicrobial Tuning of Bioactive Glass Nanoparticles Added \n\nwith Neem (Azadirachta indica) Leaf Powder, Biomed Res. Int. \n\n2014 (2014) 1\u201310. doi:10.1155/2014/950691. \n\n[29] R.F.A. Bonfim, V.R. Chitarra, R.T. Gomes, R.D. Zacarias, V.R. \n\nSantos, W.A. Vasconcelos, Antimicrobial activity of bioactive \n\nglass associated to Brazilian red and green propolis, Planta Med. \n\n75 (2009) 1078. \n\n[30] M. Cazzola, I. Corazzari, E. Prenesti, E. Bertone, E. Vern\u00e8, S. \n\nFerraris, Bioactive glass coupling with natural polyphenols: \n\nSurface modification, bioactivity and anti-oxidant ability, Appl. \n\nSurf. Sci. 367 (2016) 237\u2013248. doi:10.1016/j.apsusc.2016.01.138. \n\n[31] L. Grenho, J. Barros, C. Ferreira, V.R. Santos, F.J. Monteiro, \n\n\n\n100 \n\nM.P. Ferraz, et al., In vitro antimicrobial activity and \n\nbiocompatibility of propolis containing nanohydroxyapatite, \n\nBiomed. Mater. 10 (2015) 25004. doi:10.1088/1748-\n\n6041/10/2/025004. \n\n[32] G.G. Mori, S. da S. Rodrigues, S.T. Shibayama, M. Pomini, \n\nC.O.F. do Amaral, Biocompatibility of a calcium hydroxide-\n\npropolis experimental paste in rat subcutaneous tissue., Braz. \n\nDent. J. 25 (2014) 104\u20138. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/25140713 (accessed \n\nSeptember 18, 2016). \n\n[33] J.M. Sforcin, Biological Properties and Therapeutic Applications \n\nof Propolis., Phytother. Res. 30 (2016) 894\u2013905. \n\ndoi:10.1002/ptr.5605. \n\n[34] A. Occhipinti, A. Germano, M.E. Maffei, Prevention of Urinary \n\nTract Infection with Oximacro, A Cranberry Extract with a High \n\nContent of A-Type Proanthocyanidins: A Pre-Clinical Double-\n\nBlind Controlled Study., Urol. J. 13 (2016) 2640\u20139. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/27085566 (accessed April \n\n15, 2017). \n\n[35] Y. Tao, P.A. Pinz\u00f3n-Arango, A.B. Howell, T.A. Camesano, Oral \n\nconsumption of cranberry juice cocktail inhibits molecular-scale \n\nadhesion of clinical uropathogenic Escherichia coli., J. Med. \n\nFood. 14 (2011) 739\u201345. doi:10.1089/jmf.2010.0154. \n\n[36] D. Kim, G. Hwang, Y. Liu, Y. Wang, A.P. Singh, N. Vorsa, et \n\nal., Cranberry Flavonoids Modulate Cariogenic Properties of \n\nMixed-Species Biofilm through Exopolysaccharides-Matrix \n\nDisruption., PLoS One. 10 (2015) e0145844. \n\ndoi:10.1371/journal.pone.0145844. \n\n[37] H. Koo, S. Duarte, R.M. Murata, K. Scott-Anne, S. Gregoire, \n\nG.E. Watson, et al., Influence of Cranberry Proanthocyanidins on \n\nFormation of Biofilms by Streptococcus mutans on Saliva-Coated \n\nApatitic Surface and on Dental Caries Development in vivo, \n\nCaries Res. 44 (2010) 116\u2013126. doi:10.1159/000296306. \n\n[38] G. Feng, M.I. Klein, S. Gregoire, A.P. Singh, N. Vorsa, H. Koo, \n\nThe specific degree-of-polymerization of A-type \n\nproanthocyanidin oligomers impacts Streptococcus mutans \n\nglucan-mediated adhesion and transcriptome responses within \n\n\n\n101 \n\nbiofilms, Biofouling. 29 (2013) 629\u2013640. \n\ndoi:10.1080/08927014.2013.794456. \n\n[39] T. Kokubo, H. Takadama, How useful is SBF in predicting in \n\nvivo bone bioactivity?, Biomaterials. 27 (2006) 2907\u20132915. \n\ndoi:10.1016/j.biomaterials.2006.01.017. \n\n[40] A.L.B. Macon, T.B. Kim, E.M. Valliant, K. Goetschius, R.K. \n\nBrow, D.E. Day, et al., A unified in vitro evaluation for apatite-\n\nforming ability of bioactive glasses and their variants, J. Mater. \n\nSci. Mater. Med. 26 (2015) 115. doi:10.1007/s10856-015-5403-9. \n\n[41] Y.-Z. Liu, Y. Li, X.-B. Yu, L.-N. Liu, Z.-A. Zhu, Y.-P. Guo, \n\nDrug delivery property, bactericidal property and \n\ncytocompatibility of magnetic mesoporous bioactive glass., \n\nMater. Sci. Eng. C. Mater. Biol. Appl. 41 (2014) 196\u2013205. \n\ndoi:10.1016/j.msec.2014.04.037. \n\n[42] S. Lowel, J. Shields, M. Thomas, M. Thommes, Characterization \n\nof Porous Solids and Powders: Surface Area, Pore size and \n\ndensity, Springer s, Kluwer Academic Publishers, Dordrecht, \n\n2004. \n\n[43] G.A. Stanciu, I. Sandulescu, B. Savu, S.G. Stanciu, K.M. \n\nParaskevopoulos, X. Chatzistavrou, et al., Investigation of the \n\nHydroxyapatite Growth on Bioactive Glass Surface, J. Biomed. \n\nPharm. Eng. 1 (2007) 34\u201339. \n\nhttp://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.502.89\n\n02&amp;rep=rep1&amp;type=pdf (accessed April 30, 2017). \n\n[44] S.-J. Shih, W.-L. Tzeng, R. Jatnika, C.-J. Shih, K.B. Borisenko, \n\nControl of Ag nanoparticle distribution influencing bioactive and \n\nantibacterial properties of Ag-doped mesoporous bioactive glass \n\nparticles prepared by spray pyrolysis, J. Biomed. Mater. Res. - \n\nPart B Appl. Biomater. 103 (2014) 899\u2013907. \n\ndoi:10.1002/jbm.b.33273. \n\n[45] V. Anand, K.J. Singh, K. Kaur, Evaluation of zinc and \n\nmagnesium doped 45S5 mesoporous bioactive glass system for \n\nthe growth of hydroxyl apatite layer, J. Non. Cryst. Solids. 406 \n\n(2014) 88\u201394. doi:10.1016/j.jnoncrysol.2014.09.050. \n\n[46] J. Hum, A.R. Boccaccini, Bioactive glasses as carriers for \n\nbioactive molecules and therapeutic drugs: A review, J. Mater. \n\nSci. Mater. Med. 23 (2012) 2317\u20132333. doi:10.1007/s10856-012-\n\n\n\n102 \n\n4580-z. \n\n[47] M. Manzano, M. Vallet-Reg\u00ed, New developments in ordered \n\nmesoporous materials for drug delivery, J. Mater. Chem. 20 \n\n(2010) 5593\u20135604. doi:10.1039/b922651f. \n\n[48] N. Leta\u00efef, A. Lucas-Girot, H. Oudadesse, R. Dorbez-Sridi, P. \n\nBoullay, Investigation of the surfactant type effect on \n\ncharacteristics and bioactivity of new mesoporous bioactive glass \n\nin the ternary system SiO 2-CaO-P2O5: Structural, textural and \n\nreactivity studies, Microporous Mesoporous Mater. 195 (2014) \n\n102\u2013111. doi:10.1016/j.micromeso.2014.03.035. \n\n[49] Y.F. Goh, A.Z. Alshemary, M. Akram, M.R.A. Kadir, R. \n\nHussain, Bioactive Glass: An In-Vitro Comparative Study of \n\nDoping with Nanoscale Copper and Silver Particles, Int. J. Appl. \n\nGlas. Sci. 5 (2014) 255\u2013266. doi:10.1111/ijag.12061. \n\n[50] Y.F. Zhu, S. Kaskel, Comparison of the in vitro bioactivity and \n\ndrug release property of mesoporous bioactive glasses (MBGs) \n\nand bioactive glasses (BGs) scaffolds, Microporous Mesoporous \n\nMater. 118 (2009) 176\u2013182. \n\ndoi:10.1016/j.micromeso.2008.08.046. \n\n[51] W. Xia, J. Chang, Preparation, in vitro bioactivity and drug \n\nrelease property of well-ordered mesoporous 58S bioactive glass, \n\nJ. Non. Cryst. Solids. 354 (2008) 1338\u20131341. \n\ndoi:10.1016/j.jnoncrysol.2006.10.084. \n\n[52] X. Zhang, D. Zeng, N. Li, J. Wen, X. Jiang, C. Liu, et al., \n\nFunctionalized mesoporous bioactive glass scaffolds for \n\nenhanced bone tissue regeneration, Sci. Rep. 6 (2016) 19361. \n\ndoi:10.1038/srep19361. \n\n[53] H. Wang, S. Zhao, X. Cui, Y. Pan, W. Huang, S. Ye, et al., \n\nEvaluation of three-dimensional silver-doped borate bioactive \n\nglass scaffolds for bone repair: Biodegradability, \n\nbiocompatibility, and antibacterial activity, J. Mater. Res. 30 \n\n(2015) 2722\u20132735. doi:10.1557/jmr.2015.243. \n\n[54] D. Arcos, J. Pe\u00f1a, M. Vallet-Reg\u00ed, Influence of a SiO2-CaO-\n\nP2O5 Sol-Gel Glass on the Bioactivity and Controlled Release of \n\nCeramic/Polymer/Antibiotic Mixed Materials, Chem. Mater. 15 \n\n(2003) 4132\u20134138. doi:10.1021/cm031074n. \n\n\n\n103 \n\n[55] W. Xia, J. Chang, Well-ordered mesoporous bioactive glasses \n\n(MBG): A promising bioactive drug delivery system, J. Control. \n\nRelease. 110 (2006) 522\u2013530. doi:10.1016/j.jconrel.2005.11.002. \n\n[56] S.-J. Shih, W.-L. Tzeng, R. Jatnika, C.-J. Shih, K.B. Borisenko, \n\nControl of Ag nanoparticle distribution influencing bioactive and \n\nantibacterial properties of Ag-doped mesoporous bioactive glass \n\nparticles prepared by spray pyrolysis., J. Biomed. Mater. Res. B. \n\nAppl. Biomater. 103 (2015) 899\u2013907. doi:10.1002/jbm.b.33273. \n\n[57] Y.F. Goh, A.Z. Alshemary, M. Akram, M.R. Abdul Kadir, R. \n\nHussain, In-vitro characterization of antibacterial bioactive glass \n\ncontaining ceria, Ceram. Int. 40 (2014) 729\u2013737. \n\ndoi:10.1016/j.ceramint.2013.06.062. \n\n[58] L. Drago, D. Roman\u00f2, E. De Vecchi, C. Vassena, N. Logoluso, \n\nR. Mattina, et al., Bioactive glass BAG-S53P4 for the adjunctive \n\ntreatment of chronic osteomyelitis of the long bones: an in vitro \n\nand prospective clinical study., BMC Infect. Dis. 13 (2013) 584. \n\ndoi:10.1186/1471-2334-13-584. \n\n[59] D.C. Coraca-Huber, M. Fille, J. Hausdorfer, D. Putzer, M. \n\nNogler, Efficacy of antibacterial bioactive glass S53P4 against S. \n\naureus biofilms grown  on titanium discs in vitro., J. Orthop. Res. \n\n32 (2014) 175\u2013177. doi:10.1002/jor.22463. \n\n[60] N.C. Lindfors, Bioactive glass S53P4 as a bone graft substitute in \n\nthe treatment of osteomyelitis, Bioact. Glas. Mater. Prop. Appl. \n\n47 (2011) 209\u2013216. doi:10.1016/B978-1-84569-768-6.50009-0. \n\n[61] G.M. De Souza, Nanoparticles in restorative materials, in: \n\nNanotechnol. Endod. Curr. Potential Clin. Appl., Springer \n\nInternational Publishing, Clinical Sciences Department, Faculty \n\nof Dentistry, University of Toronto, 124 Edward St, Toronto, ON, \n\nCanada, 2015: pp. 139\u2013172. doi:10.1007/978-3-319-13575-5_8. \n\n[62] J.B. Blumberg, T.A. Camesano, A. Cassidy, P. Kris-Etherton, A. \n\nHowell, C. Manach, et al., Cranberries and Their Bioactive \n\nConstituents in Human Health, Adv. Nutr. An Int. Rev. J. 4 \n\n(2013) 618\u2013632. doi:10.3945/an.113.004473. \n\n[63] T.S. Jafarzadeh Kashi, R. Kasra Kermanshahi, M. Erfan, E. \n\nVahid Dastjerdi, Y. Rezaei, F.S. Tabatabaei, Evaluating the in-\n\nvitro antibacterial effect of Iranian propolis on oral \n\nmicroorganisms, Iran. J. Pharm. Res. 10 (2011) 363\u2013368. \n\n\n\n104 \n\n \n\n  \n\n\n\n105 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCAP\u00cdTULO III \n\n  \n\n\n\n106 \n\n  \n\n\n\n107 \n\n5 CONSIDERA\u00c7\u00d5ES FINAIS  \n\nO biovidro ativo tem sido desenvolvido para diversas aplica\u00e7\u00f5es \n\nnos processos de reparo e tratamento de infec\u00e7\u00e3o \u00f3ssea. No em tanto, o \n\nbiovidro ativo tem suas limita\u00e7\u00f5es para o tratamento de infec\u00e7\u00f5es nos \n\nleitos receptores que t\u00eam como fator causal a ader\u00eancia do biofilme \n\nmulti-esp\u00e9cies. Consequentemente a engenharia tecidual tem \n\nmodificado o biovidro ativo incorporando na sua estrutura tanto qu\u00edmica \n\ncomo f\u00edsica agentes anti-biofilme org\u00e2nicos e inorg\u00e2nicos. Nos \u00faltimos \n\nanos, as diferentes mol\u00e9culas derivadas de \u00f3xidos de metal, antibi\u00f3ticos \n\ne outros agentes sint\u00e9ticos incorporadas no biovidro ativo t\u00eam dado \n\nresultados satisfat\u00f3rios antimicrobianos, mas n\u00e3o t\u00eam apresentado \n\nresultados concluintes com respeito \u00e0 inibi\u00e7\u00e3o do biofilme. Assim, o \n\npresente trabalho explorou o estado da arte do tema para desenvolver \n\nassim part\u00edculas do biovidro ativo 58S normal e mesoporoso \n\nincorporando mol\u00e9culas de brometo, cranberry e pr\u00f3polis a fim de \n\ncombater as infe\u00e7\u00f5es \u00f3sseas associadas ao biofilme. Em princ\u00edpio, o \n\nbiovidro ativo 58S incorporando brometo mostrou resultados \n\npromiss\u00f3rios com rela\u00e7\u00e3o a inibi\u00e7\u00e3o de biofilme oral multi-especies. Por \n\noutro lado, o biovidro mesoporoso incorporando as mol\u00e9culas naturais \n\nmostrou uma alta bioatividade que \u00e9 uma caracter\u00edstica inerente do \n\nbiomaterial, sendo assim um material promiss\u00f3rio que poderia atuar \n\ncomo sistema de libera\u00e7\u00e3o localizado de agentes anti-biofilme no leito \n\nreceptor. Contudo, futuros estudos s\u00e3o necess\u00e1rios para estabelecer os \n\nagentes anti-biofilme mais efetivos para tratar as infe\u00e7\u00f5es \u00f3sseas que \n\npossam ser incorporados no biovidro ativo sem interferir com sua \n\nbioatividade inerente, nem causar efeitos citot\u00f3xicos no leito receptor.  \n\n  \n\n\n\n108 \n\n  \n\n\n\n109 \n\n6 REFER\u00caNCIAS  \n\nALLAN, I.; NEWMAN, H.; WILSON, M. Particulate Bioglass reduces \n\nthe viability of bacterial biofilms formed on its surface in an in vitro \n\nmodel. Clinical oral implants research, v. 13, n. 1, p. 53\u201358, fev. \n\n2002.  \n\nAMINI, A. R.; LAURENCIN, C. T.; NUKAVARAPU, S. P. Bone \n\ntissue engineering: recent advances and challenges. Critical reviews in \n\nbiomedical engineering, v. 40, n. 5, p. 363\u2013408, 2012.  \n\nBELLANTONE, M.; COLEMAN, N. J.; HENCH, L. L. A novel sol-gel \n\nderived bioactive glass featuring antibacterial properties. In: \n\nGIANNINI, S.; MORONI, A. (Eds.). . Bioceramics. Key Engineering \n\nMaterials. Univ London Imperial Coll Sci Technol &amp; Med, Dept Mat, \n\nLondon SW7 2BP, England. Bellantone, M (reprint author), Univ \n\nLondon Imperial Coll Sci Technol &amp; Med, Dept Mat, Prince Consort \n\nRd, London SW7 2BP, England.: Trans Tech Publications Ltd, 2000. v. \n\n192\u20131p. 597\u2013600.  \n\nCABRAL DA CRUZ, A. C. et al. Utiliza\u00e7\u00e3o de vidros bioativos como \n\nsubstitutos \u00f3sseos: Revis\u00e3o de literatura. Revista de Odontologia da \n\nUniversidade Cidade de S\u00e3o Paulo, v. 18, n. 3, p. 287\u2013295, 2006.  \n\nDAVIES, D. Understanding biofilm resistance to antibacterial agents. \n\nNature reviews. Drug discovery, v. 2, n. 2, p. 114\u201322, 2003.  \n\nDOMINGUES, Z. R. et al. Bioactive glass as a drug delivery system of \n\ntetracycline and tetracycline associated with beta-cyclodextrin. \n\nBiomaterials, v. 25, n. 2, p. 327\u2013333, jan. 2004.  \n\nEL-GHANNAM, A.; AHMED, K.; OMRAN, M. Nanoporous delivery \n\nsystem to treat osteomyelitis and regenerate bone: Gentamicin release \n\nkinetics and bactericidal effect. Journal of Biomedical Materials \n\nResearch Part B-Applied Biomaterials, v. 73B, n. 2, p. 277\u2013284, \n\n2005.  \n\nEL-KADY, A. M. et al. Synthesis, characterization and microbiological \n\nresponse of silver doped bioactive glass nanoparticles. Ceramics \n\nInternational, v. 38, n. 1, p. 177\u2013188, jan. 2012.  \n\nGALARRAGA-VINUEZA, M. E. et al. Anti-biofilm properties of \n\nbioactive glasses embedding organic active compounds. Journal of \n\nBiomedical Materials Research Part A, nov. 2016.  \n\n\n\n110 \n\nGALARRAGA-VINUEZA, M. E. et al. Inhibition of multi-species oral \n\nbiofilm by bromide doped bioactive glass. Journal of Biomedical \n\nMaterials Research Part A, 6 abr. 2017.  \n\nHENCH, L. L. The story of Bioglass\u00ae. Journal of Materials Science: \n\nMaterials in Medicine, v. 17, n. 11, p. 967\u2013978, 2006.  \n\nHOPPE, A.; G\u00dcLDAL, N. S.; BOCCACCINI, A. R. A review of the \n\nbiological response to ionic dissolution products from bioactive glasses \n\nand glass-ceramics. Biomaterials, v. 32, n. 11, p. 2757\u20132774, 2011.  \n\nHUM, J.; BOCCACCINI, A. R. Bioactive glasses as carriers for \n\nbioactive molecules and therapeutic drugs: A review. Journal of \n\nMaterials Science: Materials in Medicine, v. 23, n. 10, p. 2317\u20132333, \n\n2012.  \n\nJIA, W.-T. et al. Novel borate glass/chitosan composite as a delivery \n\nvehicle for teicoplanin in the treatment of chronic osteomyelitis. Acta \n\nbiomaterialia, v. 6, n. 3, p. 812\u2013819, mar. 2010.  \n\nJONES, J. R. Review of bioactive glass: from Hench to hybrids. Acta \n\nbiomaterialia, v. 9, n. 1, p. 4457\u201386, 2013.  \n\nKRISHNAN, V.; LAKSHMI, T. Bioglass: A novel biocompatible \n\ninnovation. Journal of Advanced Pharmaceutical Technology and \n\nResearch, v. 4, n. 2, p. 78\u201383, 2013.  \n\nLI, Y. et al. Mesoporous bioactive glass as a drug delivery system: \n\nfabrication, bactericidal properties and biocompatibility. Journal of \n\nmaterials science. Materials in medicine, v. 24, n. 8, p. 1951\u20131961, \n\nago. 2013.  \n\nMABROUK, M. et al. Effect of ciprofloxacin incorporation in PVA and \n\nPVA bioactive glass composite scaffolds. Ceramics International, v. \n\n40, n. 3, p. 4833\u20134845, abr. 2014.  \n\nMALAVASI, G. et al. Novel smart bio-nanomaterials: Bioactive \n\nglasses containing metal nano-particles conjugated with molecules \nof biological interestTechnical Proceedings of the 2012 NSTI \n\nNanotechnology Conference and Expo, NSTI-Nanotech 2012. \n\nAnais...2012Dispon\u00edvel em: \n<http://www.scopus.com/inward/record.url?eid=2-s2.0-\n\n84865036964&amp;partnerID=tZOtx3y1> \n\nMIOLA, M. et al. Antibiotic loading on bioactive glasses and glass-\n\nceramics: an approach to surface modification. Journal of biomaterials \n\n\n\n111 \n\napplications, v. 28, n. 2, p. 308\u2013319, ago. 2013.  \n\nPRABHU, M. et al. In Vitro Bioactivity and Antimicrobial Tuning of \n\nBioactive Glass Nanoparticles Added with Neem (Azadirachta indica) \n\nLeaf Powder. BioMed Research International, v. 2014, p. 1\u201310, 2014.  \n\nRIVADENEIRA, J. et al. Evaluation of antibacterial and cytotoxic \n\neffects of nano-sized bioactive glass/collagen composites releasing \n\ntetracycline hydrochloride. Journal of applied microbiology, v. 116, n. \n\n6, p. 1438\u20131446, jun. 2014.  \n\nRIVADENEIRA, J. et al. Evaluation of the antibacterial effects of \n\nvancomycin hydrochloride released from agar-gelatin-bioactive glass \n\ncomposites. Biomedical materials (Bristol, England), v. 10, n. 1, p. \n\n15011, fev. 2015.  \n\nSTEVANOVI?, M. et al. 45S5Bioglass\u00ae-based scaffolds coated with \n\nselenium nanoparticles or with poly(lactide-co-glycolide)/selenium \n\nparticles: Processing, evaluation and antibacterial activity. Colloids and \n\nsurfaces. B, Biointerfaces, v. 132, p. 208\u201315, 1 ago. 2015.  \n\nXIA, W. et al. The pH-controlled dual-drug release from mesoporous \n\nbioactive glass/polypeptide graft copolymer nanomicelle composites. \n\nEuropean journal of pharmaceutics and biopharmaceutics?: official \n\njournal of Arbeitsgemeinschaft fur Pharmazeutische \n\nVerfahrenstechnik e.V, v. 69, n. 2, p. 546\u2013552, jun. 2008.  \n\nXIA, W.; CHANG, J. Well-ordered mesoporous bioactive glasses \n\n(MBG): A promising bioactive drug delivery system. Journal of \n\nControlled Release, v. 110, n. 3, p. 522\u2013530, 2006.  \n\nXIE, Z. et al. Treatment of osteomyelitis and repair of bone defect by \n\ndegradable bioactive borate glass releasing vancomycin. Journal of \n\ncontrolled release?: official journal of the Controlled Release \nSociety, v. 139, n. 2, p. 118\u2013126, out. 2009a.  \n\nXIE, Z.-P. et al. In vivo study effect of particulate Bioglass\u00ae in the \n\nprevention of infection in open fracture fixation. Journal of Biomedical \n\nMaterials Research - Part B Applied Biomaterials, v. 90, n. 1, p. \n\n195\u2013201, 2009b.  \n\nXU, Y.-T. et al. Antimicrobial effects of a bioactive glass combined \n\nwith fluoride or triclosan on Streptococcus mutans biofilm. Archives of \n\nOral Biology, v. 60, n. 7, p. 1059\u20131065, 2015.  \n\nYAO, Q. Q. et al. Bioglass (R)-based scaffolds incorporating \n\n\n\n112 \n\npolycaprolactone and chitosan coatings for controlled vancomycin \n\ndelivery. Ceramics International, v. 39, n. 7, p. 7517\u20137522, 2013."}]}}}